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There are links between high serum urate (hyperuricemia) and many inflammatory 
diseases, yet the mechanism is obscure. Urate, the product of purine and ATP 
break down, builds up in plasma because humans lack the enzyme uricase to convert it to 
allantoin, which is freely excreted. Urate may benefit health by acting as an antioxidant 
that scavenges reactive oxygen species. However, hyperuricemia is associated with gout, 
metabolic syndrome and cardiovascular disease. Oxidative stress is also associated with all 
these inflammatory diseases. 
During oxidative stress urate is converted to several reactive electrophiles, including 
urate hydroperoxide. This novel oxidant could contribute to the adverse effects of urate. 
Urate hydroperoxide is formed when urate is oxidized to a radical that subsequently 
combines with superoxide. Activated white blood cells called neutrophils, and xanthine 
oxidase along with myeloperoxidase/lactoperoxidase, can produce urate hydroperoxide. 
Previous studies characterized the formation of urate hydroperoxide and its oxidation of 
small biomolecules. In this investigation, I explored oxidation of thiols and the thiol-
dependent enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by urate 
hydroperoxide. The effectiveness of urate hydroperoxide as a thiol oxidant was compared 
with taurine chloramine. 
Ellman’s assay for reduced thiols was used to measure depletion of cysteine residues 
on GAPDH by urate hydroperoxide and taurine chloramine. GAPDH was exposed to 
oxidants in a dose-dependent manner, then assayed by measuring its ability to catalyse the 
production of NADH. Mass spectrometry was used to identify specific modifications of 
GAPDH. 
Urate hydroperoxide oxidized exposed thiols on GAPDH and fully inactivated the 
enzyme at a ratio of about 5:1. Half of its activity was recovered by reduction with DTT. In 
comparison, taurine chloramine inactivated GAPDH at approximately 10:1 and DTT 
reduction recovered all activity. Hence, urate hydroperoxide inactivates GAPDH by 
reversible and irreversible routes. GAPDH increased in molecular mass by 132 Da with 
exposure to urate hydroperoxide, indicating the formation of a GAPDH-urate adduct. 
However, I could not identify which residue was modified with a tryptic digest. Formation 
of urate hydroperoxide during inflammation and its subsequent oxidative reactions may 
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Chapter 1. Literature Review 
1.1 Introduction 
High levels of uric acid in our blood stream are associated with inflammatory disease, 
yet the pathological mechanism eludes us (1, 2). Uric acid (7,9-di-hydro-1H-purine-
2,6,8(3H)-trione) is the product of purine and ATP break down and circulates the plasma as 
the monoanion urate, pKa 5.4 (2, 3). Mammals produce the enzyme uricase to convert urate 
to allantoin, enabling its excretion. However, humans cannot produce this enzyme because 
the uricase gene lost functionality during primate evolution (2, 4). Thus, we have a high 
concentration of urate in our blood serum, the normal range is 240 – 360 µM (2, 5). 
Elevated serum urate may have evolved to prevent dehydration, promote serum antioxidant 
activity, fat storage and bipedal locomotion by increasing blood pressure (3, 6, 7). Urate 
has antioxidant activity and is potentially the most abundant antioxidant in our bloodstream 
(3, 8). This antioxidant scavenges a number of oxidant species, thus protecting other 
biomolecules from damage (3, 9, 10). Ascorbate, a serum antioxidant, reduces urate back 
to its antioxidant state hence promoting its activity (9, 10). 
Yet, urate has a number of adverse effects on human health. Abnormally high serum 
urate, hyperuricemia, is associated with inflammatory diseases, including cardiovascular 
disease (1, 11). Hyperuricemia is characterised by inflammation and oxidative stress (5, 
12). Under these conditions, urate acts as an endogenous signal molecule to initiate a 
number of inflammatory pathways (13-15). Urate promotes the oxidation of biomolecules, 
thus acting as a pro-oxidant, during oxidative stress and in lipid environments (16-18). 
This molecule forms a number of electrophilic intermediates on the oxidative pathway to 
allantoin (figure 1). Electrophilic oxidants damage biomolecules (19). In particular, 
oxidative conditions at an inflammatory site may produce the novel oxidant urate 
hydroperoxide. This species is stable enough to diffuse to biomolecules and cause 
oxidative damage (17, 19, 20). Formation of urate hydroperoxide during hyperuricemia 
may explain the pro-oxidant effects of urate. 
In this literature review, I explain why this thesis focuses on the reactivity of urate 
hydropeorxide. A target of urate hydroperoxide oxidation could be biomolecules with thiol 
functional groups, such as cysteine and glutathione, due to their vulnerability to 
electrophiles (21, 22). In particular, urate hydroperoxide might inactivate thiol-dependent 




hydroperoxide oxidises thiol-dependent biomolecules, such as cysteine, glutathione and 
glycolytic enzyme GAPDH (26, 27). GAPDH uses an essential cysteine residue to 
covalently bind substrate glyceraldehyde-3-phosphate (GAP) (28). Oxidation of this 
residue reversibly or irreversibly inactivates GAPDH, which has repercussions for cell 
metabolism of glucose for energy (29). I aim to determine whether urate hydroperoxide 
inactivates this enzyme and the reversibility of inactivation. Mass spectrometry will be 
used to identify the structural change responsible for inactivation. 
 
 
Figure 1: Oxidation of urate to allantoin in human serum. Urate is oxidized to a radical with the lone 
electron delocalised over the purine ring. The radical can dismutate to urate and dehydrourate. Dehydrourate 
is hydrolysed to 5-hydroxyisourate, which breaks down to allantoin. Alternatively, the urate radical can 










1.2 Urate and Cardiovascular Disease 
Urate is associated with cardiovascular disease (11), gout (5), renal disease (30), 
rheumatoid arthritis (12), hypertension (15), diabetes (2), metabolic syndrome (31) and 
cancer (32-34) (figure 2). The association between hyperuricemia and cardiovascular 
disease is debated. The literature has two positions: hyperuricemia is independently 
causative of cardiovascular disease or is a negative side effect of the disease. The 
association between hyperuricemia and cardiovascular disease in the general population is 
weak (11, 35-40). However, the association becomes stronger for patients with a high risk 
of cardiovascular disease. This includes patients with diabetes (41), hypertension (42, 43) 
and survivors of myocardial infarction or stroke (44-46) (table 1). For example, the GISSI-
Prevenzione trial examined over 10,000 patients with myocardial infarction over 3.5 years. 
All-cause and cardiovascular disease mortality is significantly higher for patients with 
hyperuricemia. However, Levantesi et al. (46) did not have a balanced gender ratio, where 
9,247 men and 1,593 women were examined, and did not compare to a healthy cohort. 
Studies on a specific population are not generalizable to other populations. The National 
Health and Nutrition Examination Survey (NHANES) III presented opposing evidence. 
Zalawadiya et al. (40) surveyed 11,009 healthy US participants and did not find an 
independent association between hyperuricemia and cardiovascular disease or coronary 
heart disease mortality (40). This study examined multiple ethnicities and could be a good 
representation of the US population. To verify hyperuricemia is associated with 
cardiovascular disease, a large and multicultural, cross-population study is required to 






Figure 2: High serum urate due to a western diet can lead to inflammatory disease. Urate enters our 
body through diet and the consumption of purines. Purine breaks down to inosine, hypoxanthine, xanthine 
and urate. Urate enters the blood serum and is excreted through urine or the bile. The loss of uricase during 
human evolution led to build up of urate in human serum. Overconsumption of purine leads to hyperuricemia. 
Urate crystals form in the joints, causing gout. Pro-oxidant effects of urate aggravate oxidative stress and 
may explain the association between hyperuricemia and cardiovascular disease. Excess urate in urine 











 Table 1: Studies that explored the clinical association between serum urate and cardiovascular disease.  
The association is stronger for patients with a high risk of cardiovascular disease. All examples used 
multivariate analysis. Table adapted from (47). 
 
Study References N Urate (µM) Major findings Independent 
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> 450 Serum urate is associated with 
cardiovascular disease in patients with 
high risk of cardiovascular disease. 
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Chinese 
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2008 
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> 380 Serum urate is independently associated 
with cardiovascular disease risk and all-
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Wang, J (42) 2,725 
M/F 
> 420 Serum urate independently predicts all-
cause and cardiovascular disease 





1.3 Urate and Inflammation 
Inflammatory disease is caused by an immune response in the absence of pathogenic 
threat, or sterile conditions. Immune cells are recruited by damage-associated molecular 
patterns (DAMP), which are endogenous molecules secreted by dying cells (49). Necrotic, 
or dying cells also produce reactive oxygen species (ROS), which are harmful oxygen and 
peroxide radicals (50). Immune cells respond by releasing hydrolase, which cleave proteins, 
thus effecting an adjacent cell’s ability to survive (51). Urate should be counted among the 
DAMP which exacerbate a sterile inflammatory response (13). Urate crystals upregulate 
the NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome (14, 52, 
53). The NLRP3 inflammasome activates factors responsible for promoting an 
inflammatory response (54). Urate also depletes nitric oxide (NO), which is an endogenous 
signalling molecule for inflammatory pathways (15, 55, 56). Urate activates 
proinflammatory cytokines. These factors recruit the inflammatory response (30, 57-60). 
 
1.3.1  NLRP3 Inflammasome 
Urate could aggravate inflammation by activating the NLRP3 inflammasome, a 
protein complex in the inflammation signalling pathway (14, 52, 53). When the 
inflammasome forms it activates proinflammatory cytokines interleukin-1 beta/8 (IL-1β, 
IL-18) (52, 53). Exposure of THP-1, a human leukaemia monocyte cell line, to urate 
activated IL-1β. Thus the inflammasome formed. Activation of these cytokines was lost 
when a preceding enzyme on the inflammasome pathway, caspase-1, was inhibited (14). 
Martinon et al. (14) presented strong evidence for the IL-1β activation in response to urate, 
yet inflammasome activity and formation was not directly measured. Injection of urate 
crystals into the inflamed lungs of mice led to IL-1β activation and recruitment of immune 
cells lymphocytes and neutrophils (53). Whereas injection of urate crystals into 
inflammasome-deficient mice did not recruit an inflammatory response (53). The 
applicability of these studies is limited by the use of urate crystals, which form in the 
synovial fluids during gout (5). Urate crystals do not form during most inflammatory 
disease, however are found in atherosclerotic plaques. Interestingly, urate crystals in an 
atherosclerotic plaque were colocalized with superoxide generating enzyme xanthine 
oxidase. Hence there may be a pro-oxidant element to the adverse effects of urate crystals 




1.3.2  Nitric Oxide 
Depletion of NO, an inflammatory signalling molecule and relaxant of the arteries, 
could be a mechanism by which urate promotes inflammation (15, 55, 56). NO reacts with 
urate to produce 6-aminouracil. This reaction occurred when NO was bubbled through 
buffer, human serum and human aortic endothelial cell lysate with urate (55). Gersch el al. 
(55) exposed urate to NO in anaerobic conditions, hence these results have limited 
relevance to oxygenated endothelium, though, hypoxia could occur during inflammation 
and atherosclerosis (62). Under aerobic conditions, NO added to urate to form nitrosylated 
urate. This molecule decayed at a half-life of 2.2 min and transferred the NO moiety to 
glutathione (63). Suzuki (63) did not explore whether nitrosylated urate or glutathione 
could release NO. NO could be depleted or carried by nitrosylated urate (63).  
Alternatively, urate could deplete NO by activating quencher arginase. In endothelial 
cells NO is exclusively synthesised from L-arginine, which can be diverted to urea and 
ornithine by arginase. Porcine pulmonary arterial endothelial cells treated with urate had a 
lower concentration of NO and cGMP, the secondary signalling molecule for the NO 
pathway. Urate activated arginase by lowering its affinity constant (15). Zharikov et al.’s 
(15) cell model was appropriate for human endothelium, but the authors studied one of 
many quenchers of NO. Depletion of NO might lead to endothelial dysfunction, which is a 
key factor for cardiovascular disease (55, 64). NO may have pro- or anti-inflammatory 
effects (64-66). 
 
1.3.3  Proinflammatory Cytokines 
Proinflammatory cytokines are proteins secreted by cells to recruit an inflammatory 
response (67). A range of proinflammatory cytokines are upregulated by urate: 
cyclooxygenase-2, cytosolic phospholipases A2, IL-1α, IL-1β and monocyte 
chemoattractant protein-1 (MCP-1) (30, 57-60). Incubation of rat vascular smooth muscle 
cells with a physiological concentration of urate increased MCP-1 mRNA and protein 
expression. The addition of ROS inhibitors halved MCP-1 protein expression, hence urate 
upregulated this protein through a pro-oxidant pathway (58). In another paper, vascular 
smooth muscle cells exposure to urate increased cyclooxygenase-2 mRNA and protein 
expression. Cell proliferation was promoted (30). The strength of these papers was the use 
of rat vascular smooth muscle cells to model human blood vessels. In humans, vascular 




blood cell (68). Urate’s upregulation of these cytokines could promote cell proliferation 
and immune response during atherosclerotic plaque growth (68). 
 
1.4 Urate as an Antioxidant 
Antioxidants are preferentially oxidized to stable products by oxidants, hence 
preventing damage to biomolecules. Urate is a proven antioxidant and is responsible for > 
60% of the antioxidant activity in blood serum (69). Urate depletes singlet oxygen (3), 
peroxyl and hydroxyl radicals (3, 70-72), peroxynitrite (73-75) and oxo-heme oxidants (3, 
69). Transition metal ion coordination to urate hinders their reactivity (76). These oxidants 
are biologically relevant. Singlet oxygen is formed during photooxidation by 
photosensitisers such as riboflavin (67). Hydroxyl radicals are very powerful oxidants 
formed during radiolysis of water (3, 67).  Oxo-heme oxidants form when the iron of 
hemoglobin binds oxygen and peroxide (3, 67). Transition metals generate hydroxyl 
radicals and superoxide (70). Peroxyl radicals are formed during the breakdown of organic 
peroxide (67). Peroxynitrite is a cytotoxic oxidant formed when NO adds to superoxide 
(73). Thus, urate’s removal of these species is important for maintaining a balance between 
antioxidants and pro-oxidants in serum. 
Urate's antioxidant activity yields a urate radical with an unpaired electron 
delocalised over the purine ring (77). Ascorbate recovers urate by reducing the radical, thus 




Figure 3: Urate has an antioxidant cycle with ascorbate. Urate scavenges singlet oxygen, oxo-heme 
oxidants, peroxynitrite, peroxyl and hydroxyl radicals to form the urate radical. The urate radical is also 
formed enzymatically by myeloperoxidase and lactoperoxidase. The radical electron of the urate radical is 
delocalised over the purine ring. Ascorbate is oxidized by the urate radical, thus regenerating urate. Figure 





1.4.1  Singlet Oxygen, Peroxyl and Hydroxyl Radicals 
Ames et al. (3) heralded the antioxidant theory for urate by studying its depletion 
during gamma irradiation. Hydroxyl radicals and singlet oxygen depleted more than half of 
physiological urate (300 µM) in five minutes. These radicals consumed 20% of ascorbate 
in the same conditions (3). The results for hydroxyl radicals were not exclusive since 
gamma irradiation induces many ROS (67). Urate’s ability to scavenge these oxidants 
might be vital for preventing damage to biomolecules during irradiation (3). 
Urate's antioxidant activity with peroxyl radicals is debated in the literature (9, 10, 71, 
72). Azo-initiators 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH) and 2,2'-
Azobis (2,4-dimethylvaleronitrile) (AMVN) can be used to initiate organic peroxidation 
(67). Urate prevented inactivation of lysozyme, double-strand breaks in DNA plasmids and 
lipid peroxidation by AAPH-induced peroxyl radicals. Yet, urate had no effect on AMVN-
induced peroxidation. The former oxidant is water-soluble while the latter is lipid-soluble, 
hence urate may not be able to scavenge across the lipid-water partition (71). Urate’s 
antioxidant activity with lipid peroxyl radicals is prolonged and replenished by the 
presence of ascorbate (9, 10). Frei et al. (9, 10) found that urate and ascorbate were 
depleted sequentially by peroxyl radicals, indicating urate is the first line of antioxidant 
defence. Ascorbate reduced the urate radical back to urate to form an antioxidant cycle (9, 
10). Urate scored poorly with the total oxidant scavenging assay compared to glutathione, 
when scavenging hydroxyl and peroxyl radicals (72). Thus, there are disagreements in the 
literature for urate’s effectiveness with peroxyl radicals which may be explained by urate’s 
inability to scavenge lipid environments (9, 10, 71). 
 
1.4.2  Peroxynitrite 
Urate's ability to scavenge peroxynitrite, an oxidant and nitrating agent, is supported 
in the literature (73-75). Tyrosine and guanine are common targets of this oxidant (73). 
Urate prevented peroxynitrite-induced tyrosine nitrosylation and inhibited guanine 
nitration (73). Yet, urate failed to scavenge peroxynitrite with the pyrogallol red assay and 
was the least effective scavenger of peroxynitrite compared to ascorbate and glutathione. 
This experiment was performed in the presence of bicarbonate to model physiological 
conditions (73). Peroxynitrite oxidises bicarbonate, forming a carbonate radical which 
propagates the effect of peroxynitrite (67). In a similar study, Kuzkaya et al. (74) measured 




bicarbonate. Urate’s antioxidant activity yielded a carbon-centred radical, which ascorbate 
reduced to form an ascobyl radical. The presence of ascorbate or thiols tripled urate’s 
antioxidant capacity (74) Urate’s antioxidant activity therefore coexists with ascorbate, 
forming an antioxidant cycle (9, 10, 74). Urate’s antioxidant activity was ineffective 
against superoxide (74). 
 
1.4.3  Oxo-Heme Oxidants 
Ames et al. (3) published the only paper to show that urate scavenges oxo-heme 
oxidants in metalloenzymes. Ames et al. (3) oxidized haematin, a Fe-porphyrin co-
ordinated to a hydroxide; and methemoglobin, an alternative oxidation state of 
haemoglobin; with hydrogen peroxide. Half of urate (300 µM) was consumed in four 
minutes as it scavenged the oxo-heme adducts (3). 
 
1.4.4  Metal Ion Coordination 
Davies et al. (76) published the only paper to link urate coordination of metal ions to 
antioxidant activity. Urate completely prevented the oxidation of ascorbate in a solution of 
Fe3+. Allantoin was not formed, hence urate coordinated the metal ion instead of 
scavenging oxidants. Thus, urate lowered the metal ion's reductive potential and reactivity 
as an oxidant (76). However, Davies et al. (76) used urate 1-10 µM; which is well below 
the physiological concentration of urate. Few papers describe urate's antioxidant activity in 
hyperuricemia. Other studies examined urate coordination to metal ions but did not 
measure the effect on oxidation (79, 80). Fe ions are abundant in blood serum but are 
always chelated to metalloenzymes (81). ‘Free’ Fe ions, due to the overconsumption of Fe, 
produce ROS which damage biomolecules (82). This antioxidant activity may be crucial in 
preventing mutagenesis and carcinogenesis during Fe poisoning. 
 
1.5 Urate as a Pro-oxidant 
Pro-oxidants are species that directly or indirectly promote oxidative stress (83). 
Many antioxidants can act as pro-oxidants under specific conditions. Ascorbate and 
phenolics promote copper-induced oxidation of oxidised low density lipoprotein (oxLDL), 




acts as an antioxidant or pro-oxidant depending on the microenvironment (figure 4). Urate 
is a conditional pro-oxidant of low density lipoprotein (LDL) (16, 75, 86, 87). Urate 
upregulates NADPH (reduced nicotinamide adenine dinucleotide phosphate) oxidase 
(NOX), which generates ROS (18, 88, 89). A urate peroxyl radical inactivates yeast alcohol 
dehydrogenase (YADH) (90) and α1-antitrypsin (A1AT) (73, 91). Urate oxidation produces 
urate hydroperoxide, which could be a powerful oxidant of biomolecules (5, 12, 17, 19, 20). 
 
 
Figure 4: Urate’s pro-oxidant effects have physiological repercussions for inflammatory disease. 
Depletion of NO could lead to endothelial dysfunction, the lack of ability to control vascular dilation in blood 
vessels. Activation of cytokines: nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), C-
reactive protein (CRP) and MCP-1 aggravate inflammation. Activation of NOX produces ROS, hence 
elevates oxidative stress. Urate directly affects the renin-angiotensin system, as evident in hyperuricemia’s 
association with high blood pressure. These mechanisms feed the pathology of atherosclerosis and reduced 
glomerular filtration rate (GFR), a measure of kidney function. Reduced GFR, insulin resistance, diuretics 
and diet elevate serum urate. Figure adapted from (92). 
 
1.5.1  Low Density Lipoprotein 
Urate increases the oxidation of LDL, despite its well documented antioxidant 
capacity (16, 75, 86, 87). Urate acts as a pro-oxidant or antioxidant of LDL during copper-
induced (CuSO4) oxidation (16). Urate addition alongside the oxidant CuSO4 extended the 
lag phase of lipid oxidation, hence acted as an antioxidant. On the contrary, when addition 
of urate followed CuSO4 the rate and amount of lipid peroxides increased, hence urate 
acted as a pro-oxidant (16). Free metals are rare in serum, but there is growing evidence 




94). Urate’s pro-oxidant activity with LDL is not limited to copper-induced oxidation. A 
urate concentration equivalent to hyperuricemia (500 µM) doubled oxLDL formation 
during peroxynitrite-induced oxidation (75). These results are pathologically relevant 
because oxLDL is linked to atherosclerosis (95-97). Urate is present in the muscular 
endothelium where LDL becomes trapped and oxidized (16). Urate may act as a pro-
oxidant for LDL oxidation, hyperuricemia would promote these effects. 
Urate’s pro-oxidant effect was evident when copper-induced LDL oxidation was 
examined in human serum ultra-filtrate. Ultra-filtrate with 10 µM urate delayed 
peroxidation initiation. However, ultra-filtrate brought forward the propagation phase when 
it was added after initiation. Ultra-filtrate lost antioxidant and pro-oxidant activity when 
uricase removed urate, this is strong evidence that urate was responsible for enhancing 
oxidation of oxLDL (87). Urate’s pro-oxidant and antioxidant activity for LDL is evident 
ex vitro and in vitro (16, 75, 86, 87). The discrepancies in the literature for urate’s effect on 
oxLDL can be explained by the experimental method. Previous studies (9, 10, 98, 99) 
added urate prior to peroxidation initiation, hence did not account for the effect of 
oxidative stress on urate.  
 
1.5.2  NADPH Oxidase 
A number of studies have shown that urate upregulates neutrophil phagosomal and 
non-phagosomal NOX (18, 88, 89). The hydrophobic and oxidative nature of adipocytes 
provides the perfect microenvironment for urate to act as a pro-oxidant (18). Urate uptake 
by mouse 3T3-L1 differentiated adipocytes increased intracellular ROS. Urate increased 
uptake of NOX subunits p67phox and p47phox into membranes, enabling activation of non-
phagocyte NOX. NOX transfers electrons from reduced nicotinamide adenine dinucleotide 
phosphate (NADPH) to oxygen to yield superoxide, hence generating ROS (18). This 
study is limited by the fact that the authors did not directly measure NOX, and many 
isoforms of NOX exist in adipocytes which may not require the subunits measured. The 
mechanisms of non-phagocyte NOX activation are elusive, however p67phox and p47phox 
are required for phagocyte NOX activation (100). Hence, this pro-oxidant effect could be 
significant for neutrophils at an inflammatory site (89). Also, 60 µM urate generated the 
most ROS; serum urate concentration is many times greater (230-360 µM) (2). A 




to activating NOX. In support of this, NOX inhibitors did not completely remove ROS. 
Obesity accompanies hyperuricemia, hence these results are physiologically relevant (101). 
Urate also activated the NOX of human aerotic smooth muscle cells (88). Treatment 
with urate promoted cell proliferation and the Endothelin-1, which signals the contraction 
of blood vessels (vasoconstrictor) and associated with cardiovascular disease (88, 102). 
The uptake of the p47phox subunit into microsomal membranes increased, thus urate 
activated NOX. It was apparent that urate acted through a pro-oxidant mechanism since 
pre-treatment of the cells with antioxidant N-acetylcysteine prevented cell proliferation 
(88). These results link the pro-oxidant effects of urate to damage vascular smooth muscle 
cells during atherosclerosis (30, 58, 88).  
 
1.5.3  Inactivation of Enzymes 
The literature for urate's redox interaction with enzymes is lacking. Physiological 
urate (240 µM) enhanced inactivation of gamma irradiated A1AT, an anti-inflammatory 
serpin for elastase (91). A urate peroxyl radical formed via ROS oxidation was thought to 
be responsible for inactivation of this enzyme. Addition of ascorbate recovered urate’s 
antioxidant activity (91). The peroxyl radical could be a reactive intermediate to urate 
hydroperoxide which oxidises essential A1AT residues. Conflicting results were published 
more than a decade later by Whiteman et al. (73). Very high urate (1000 µM) offered a 
small but significant protection against peroxynitrite-induce A1AT inactivation. Urate’s 
antioxidant activity increased in the presence of bicarbonate (73). The discrepancy between 
these papers is due to the oxidant used. Aruoma and Halliwell (91) used irradiation to 
generate ROS. Urate scavenged the ROS to form a radical, and then combined with oxygen 
or superoxide to form the peroxyl radical. Whereas Whiteman et al. (73) used peroxynitrite 
prepared from peroxide and nitrite. Superoxide was absent in the reaction system, hence 
the peroxyl radical was unlikely to form (73). A serum urate concentration of 1000 µM is 
not an unreasonable concentration to model serum urate for humans. During hyperuricemia 
and starvation serum urate can rise to > 1000 µM (103). 
A similar mechanism was proposed for inactivation of Yeast alcohol dehydrogenase 
(YALDH) in a study by Kittridge and Wilson (90). Addition of a very high concentration of 
urate (1000 µM) to an irradiated solution of YALDH resulted in a sharp loss of enzyme 
activity. Similarly to Aruoma and Halliwell (91), a urate peroxyl radical was thought to 




nitrogen, hence superoxide is essential for peroxyl radical formation (90). A flaw in 
Kittridge and Wilson’s (90) study is that they did not show inactivation for a 
physiologically relevant enzyme. YALDH is not found in humans and urate failed to 
inactive hog lactate dehydrogenase (LDH) (90). Kittridge and Wilson (90) and Aruoma and 
Halliwell (91) demonstrated a urate peroxyl radical, which could be analogous to urate 
hydroperoxide, can oxidise enzymes. The urate peroxyl likely oxidized catalytic residues. 
YALDH is a thiol-dependent enzyme, oxidation of the cysteine ligands to sulfinic or 
sulfonic acids results in loss of the catalytic Zn (104). The catalytic methionine residues of 
A1AT are oxidized to sulfoxide adducts, resulting in irreversible inactivation (105). Further 
research is required to elucidate the pro-oxidant effect of urate on enzymes. 
 
1.5.4  Urate Hydroperoxide 
The biological context of urate hydroperoxide formation can be understood when we 
recall that activated white blood cells called neutrophils have all the machinery to produce 
urate hydroperoxide. Neutrophils are recruited to inflammatory sites where they are 
trapped and spill their oxidative contents (106, 107). This includes myeloperoxidase, which 
oxidises urate to the radical and NOX, which generates superoxide (17, 20, 108). 
Superoxide adds very quickly to the urate radical, at rate constant k = 8 x 108 M-1s-1, to 
form urate hydroperoxide (17, 19, 109). During hyperuricemia, the concentration of urate 
overwhelms other antioxidants leading to oxidative stress. Therefore, urate hydroperoxide 
could be formed at an inflammatory site during neutrophil invasion and hyperuricemia (20). 






Figure 5: Pathways for urate hydroperoxide formation in vitro and in vivo (theoretically) by 
photooxidation or inflammatory processes. The basic process involves conversion of urate to a radical and 
combination of the radical with superoxide to form urate hydroperoxide. In vitro urate hydroperoxide can be 
formed at high concentration using the riboflavin photocycle. During this process superoxide is generated 
and urate is converted to a radical. The proposed in vivo system for urate hydroperoxide formation involves 
neutrophil oxidants myeloperoxidase and superoxide. Neutrophils spill myeloperoxidase and hydrogen 
peroxide into inflammatory site during inflammation. These can convert urate to a radical. Neutrophil 
oxidative bursts produce superoxide, which adds to the urate radical. These reactions are described further in 
the next chapter. Urate hydroperoxide oxidises several biomolecules forming electrophilic product 
hydroxyisourate. Figure adapted from (20).  
 
A recent study by Patrício et al. (20) characterised urate hydroperoxide’s reaction 
with small biomolecules. Urate hydroperoxide absorbs ultraviolet light at 308 nm: ε(308) = 
6,540 ± 380 M-1cm-1, this can be visualised on a spectrophotometer. This molecule decays 
quickly at half-life 41 min at room temperature (20). Urate hydroperoxide oxidized 
methionine to methionine sulfoxide, cysteine to cystine and glutathione to glutathione 
disulfide, in a two-electron reaction. The urate oxidative product was hydroxyisourate. 
Urate hydroperoxide had no effect on histidine, lysine, taurine or tryptophan (20). Urate 
hydroperoxide has not been studied with enzymes or larger biomolecules. Theoretically, 
urate hydroperoxide could act like lipid hydroperoxides. These species are powerful 








The association between serum urate and gout was proposed 150 years ago (111), yet 
our understanding of the pathology of hyperuricemia and inflammatory diseases is 
incomplete. The literature shows evidence for urate acting as an antioxidant, pro-oxidant 
and having pro-inflammatory effects. Urate can deplete NO (15, 55, 56), activate the 
NLRP3 inflammasome (14, 52, 53) and upregulate cytokines (30, 57-60) to exacerbate 
inflammation. These mechanisms recruit a sterile inflammatory response leading to the 
formation of ROS and tissue damage. Urate’s inflammation mechanisms are intertwined 
with its pro-oxidant effects.  
Urate is an abundant antioxidant in humans and scavenges a range of oxidant species: 
singlet oxygen (3), peroxyl and hydroxyl radicals (3, 70-72), peroxynitrite (73-75) and 
oxo-heme oxidants (3, 69). Nonetheless there are flaws in urate's antioxidant activity. Urate 
cannot scavenge radicals into lipid environments, it must be regenerated by ascorbate and 
it cannot scavenge superoxide (74, 76, 78). Urate’s antioxidant ability during 
hyperuricemia and the depletion of antioxidants is not well understood. High 
concentrations of urate should help not hinder inflammatory diseases by removing ROS 
that initiate and propagate inflammation (112). Yet, hyperuricemia is associated with many 
inflammatory diseases (5, 11, 12, 30).  
Like other antioxidants, urate has pro-oxidant activities in specific 
microenvironments. Urate oxidises LDL (16, 75, 86, 87), upregulates NOX (18) and 
inactivates enzymes YALD (90) and A1AT (73, 91). Urate-induced oxidation of LDL has 
many supporting papers, but the evidence for NOX activation and enzyme inactivation is 
sparse. These mechanisms are insufficient to justify urate’s association with cardiovascular 
disease. A new and convincing mechanism for urate’s pro-oxidant effects involves 
formation of urate hydroperoxide by enzymes xanthine oxidase and peroxidise, or 
riboflavin photooxidation (5, 12, 17, 19, 20). This novel oxidant depletes methionine, 
cysteine and glutathione (20). Urate hydroperoxide’s effect on enzymes has not been 




be seen. However, neutrophils have all the mechanisms to produce urate hydroperoxide 
during the inflammatory response (17).  
 
1.7 Summary 
My literature search leads me to conclude that urate can be an antioxidant or pro-
oxidant depending on its concentration and the oxidative state of blood serum. Basal urate 
undergoes an antioxidant cycle in which urate is oxidized by ROS, myeloperoxidase or 
lactoperoxidase, and is recovered by ascorbate. During hyperuricemia, depletion of 
antioxidants and in lipid environments; urate acts as a pro-oxidant to directly and indirectly 
produce oxidant species. Thus, urate ceases to provide antioxidant defence and tips the 
balance to oxidative stress, favouring the development of inflammatory disease (figure 6). 
Concentration and oxidative stress affects to urate’s antioxidant capacity. Thus, urate as a 
pro-oxidant does not conflict with its roles an antioxidant in vivo. Urate follows Paracelsus' 
famous philosophy: "The dose makes…a poison" (113). 
 
Figure 6: A healthy human body balances pro-oxidant formation with the antioxidant defence system  
(homeostasis). During oxidative stress the antioxidant defence system is overwhelmed by ROS. Oxidative 
stress characterises inflammatory disease, including cardiovascular disease, ischemia/reperfusion injury, heart 




Chapter 2. Optimising the Formation of Urate Hydroperoxide 
2.1 Introduction 
Urate hydroperoxide is transient and highly reactive (19, 20). For this chapter I wanted to 
produce a high concentration of urate hydroperoxide to use in proceeding experiments and 
to study its formation. Urate hydroperoxide can be formed in vitro by riboflavin 
photooxidation or by enzymes xanthine oxidase and myeloperoxidase/lactoperoxidase (17, 
19, 20, 77).  These systems produce a urate hydroperoxide of the same structure (20). 
 
 
Figure 7: Riboflavin undergoes a photooxidation cycle to oxidise urate to urate hydroperoxide. Light 
promoted riboflavin (Rib) to a higher energy state (1Rib*), this rearranges to form a radical (3Rib*). The 
riboflavin radical is reduced by urate to form a riboflavin radical anion (2Rib-) and the urate radical. The 
riboflavin radical anion is oxidised by oxygen to form native riboflavin and superoxide. Thus, riboflavin 
receives an electron from urate and passes it to oxygen to act as a catalyst. The urate radical and superoxide 
combine to produce urate hydroperoxide. Figure adapted from (77). 
 
Urate hydroperoxide can be formed at a high concentration with type I riboflavin 
photooxidation (20, 77). When riboflavin is illuminated with light at 440 nm it forms an 
excited state. The excited state rearranges to a radical with two extra electrons (115, 116). 




products, the urate radical and superoxide, combine to form urate hydroperoxide (figure 7) 
(77, 115, 116). The resulting hydroperoxide was catalase-resistant and quenched by 
superoxide dismutase, indicating formation of urate hydroperoxide (77). Patrício et al. (20) 
optimised the formation of urate hydroperoxide by exposing 600 µM urate to ultraviolet A 
light (365 nm) for 10 min. This method produced 300 µM urate hydroperoxide (20).  
A compelling mechanism for the formation of urate hydroperoxide by 
myeloperoxidase was published by Meotti et al. (17). Myeloperoxidase typically catalyses 
the oxidation of chloride and hydrogen peroxide to hypochlorous acid (5, 12, 17). This 
peroxidase also performs a one-electron oxidation of urate to form a urate radical (17). 
Myeloperoxidase uses a peroxidase cycle, where the heme cycles through states compound 
I and II by redox reaction with substrates (117). Compound I catalyses the oxidation of 
urate with a first order rate constant k = 4.6 x 105 M-1s-1. This is significantly higher than 
the rate constant for chloride catalysis k = 2.5 x 104 M-1s-1. Compound II oxidises urate at 
second order rate constant k = 1.7 x 104 M-1s-1. In spite of the high rate constants, 
myeloperoxidase preferentially catalyses the production of hypochlorous acid (17). 
Myeloperoxidase’s preference for chloride may be the result of high chloride concentration 
(100 µm) in neutrophil phagocytes (108). In vitro production of urate hydroperoxide 
involves use of xanthine oxidase to generate superoxide. Superoxide added to the urate 
radical to form approximately 20 µM urate hydroperoxide from > 100 µM urate (17). 
Lactoperoxidase is antibacterial enzyme catalyses the two-electron oxidation of 
thiocyanate and hydrogen peroxide to hypothiocyanite. This peroxidase also converts urate 
to the urate radical. Urate was oxidized by compound I at a second-order rate constant k = 
1.1 x 107 M-1s-1 (19). This rate is the highest of lactoperoxidase's substrates and > 20 times 
greater than catalysis by myeloperoxidase (17, 19). Compound II reduced urate in a 
second-order reaction with rate constant k = 8.5 x 103 M-1s-1 to produce another urate 
radical. An enzyme system of xanthine oxidase, lactoperoxidase and their substrates 





Figure 8: The xanthine oxidase/lactoperoxidase system to form urate hydroperoxide in vitro. The 
following substances combined in phosphate: hypoxanthine, urate, lactoperoxidase and xanthine oxidase (the 
initiator). Hypoxanthine is the substrate for xanthine oxidase, which generates superoxide, which dismutases 
to hydrogen peroxide. Lactoperoxidase converts urate and hydrogen peroxide to the urate radical. The urate 
radical and superoxide combine to form urate hydroperoxide. To stop the reaction, catalase and superoxide 
dismutase were added to deplete hydrogen peroxide and superoxide, hence quenching urate hydroperoxide 
formation. Figure adapted from (19). 
 
The xanthine oxidase/lactoperoxidase system was chosen to produce urate 
hydroperoxide because I did not have the UV lamps required for riboflavin photooxidation.  
The use of enzymes to form urate hydroperoxide is quick and simple. However, enzymes 
create interference, their activity is variable and this system forms less urate hydroperoxide 
than riboflavin photooxidation. The goal of this chapter is to optimise the formation of 






2.2 Materials and Methods 
2.2.1 Materials 
Substances and solutions used throughout experimental work were put in table 2.  
 
Table 2: Description of substances and solutions used to perform the cytochrome c assay, ferrous 
oxidation-xylenol orange assay (FOX) and the xanthine oxidase/lactoperoxidase system. The preparation 
and company sourced were described. Buffers were autoclaved before use. 
Substance Preparation Company 
Catalase from bovine 
liver 
Stock of 2 mg/mL dissolved in phosphate buffer. Sigma, C40 
Cytochrome c from 
equine heart 




Stock of 10 mM dissolved in phosphate buffer. Sigma, D1133 
Ferrous Ammonium 
Sulfate 
 Baker Reagents 
FOX reagent (modified) In 25 mL MilliQ: 400 µM xylenol orange, 1 mM 
ferrous ammonium sulfate, 400 mM sorbitol, 200 
mM sulfuric acid. 
 
Hydrogen Peroxide Stock of 30% solution diluted to 20 µM in MilliQ 
using molar extinction coefficient: ε(240) = 43.6 
M-1cm-1 (118). 
LabServ, BSPA5.500 
Hypoxanthine Stock of 10 mM in phosphate buffer, heated at 
70 °C for 2 min to dissolve before use. 
Sigma, H9377 
Phosphate buffer Approximately 80:20 of 50 mM NaH2PO4 and 50 





 BHD, 102034B 
Lactoperoxidase from 
bovine milk 
Dissolved in phosphate buffer at 1mg/mL, 
concentration determined with molar extinction 
coefficient: ε(412) = 112.3 mM-1cm-1. 
Sigma, L2005 




         Anhydrous, Labserv, 
BSPSO766.500 
D-Sorbitol  Sigma, S1876 
Sulfuric acid Concentrated stock 18.76 M. AnalaR, 102761 
Superoxide dismutase 
from bovine liver 
Stock of 2 mg/mL dissolved in phosphate buffer 
and diluted 10 times. 
Sigma, S7571 
Uric acid In 10 mL MilliQ: 1 mM was dissolved in 1 ml 0.1 
mM sodium hydroxide. 
Sigma, U2625 
Xanthine oxidase from 
bovine milk 
Diluted at 1:20 ratio in phosphate buffer. This 
dilution was equivalent to approximately 90 µM. 
The extinction coefficient of xanthine oxidase was 








2.2.2 Cytochrome C Assay of Superoxide Production by Xanthine Oxidase 
The cytochrome c assay was used to determine superoxide production by xanthine 
oxidase. The cytochrome c assay involved reduction of ferric to ferrous cytochrome c by 
superoxide. The colour change in the cuvette was orange to pink. Ferrous cytochrome c 
absorbed light at 550 nm (120). The following substances were mixed in plastic cuvettes in 
50 mM phosphate buffer: 240 µg/mL cytochrome c, 100 µM DTPA, 100 µM hypoxanthine. 
Superoxide dismutase (10 µg/mL) was added as a negative control. The final volume was 1 
mL. The Hitachi spectrophotometer (UV solutions Application program no. 2J24311-04 
(build556)) was set to time scan, six cell mode. The spectrophotometer measured 
absorbance (-0.1 – 1) at 550 nm for 300 sec. Other setting included: spectral band width = 
0.5 nm and lamp change mode = auto for 325 nm. The spectrophotometer was blanked 
with all substances except xanthine oxidase, 450 nM of this enzyme was added to initiate 
the assay. The initial rate was calculated for the first 30 sec as A.min-1 (ΔA). This value 
was used to calculate superoxide production by xanthine oxidase: 
 
Samples were made in triplicate. Firstly, the concentration of enzyme of interest, 
xanthine oxidase, was optimised. The volume of 90 µM xanthine oxidase injected into the 
cuvette was varied to achieve concentrations 0 – 1800 nM. Next, the concentration of 
xanthine oxidase’s substrate, hypoxanthine, was varied by creating a dilution series in 
phosphate buffer. Each dilution was transferred (100 µL) into plastic to achieve 
concentrations 0 – 100 µM. Superoxide production was plotted against xanthine oxidase or 
hypoxanthine concentration. 
 
2.2.3 Xanthine Oxidase/Lactoperoxidase System Photometry 
The xanthine oxidase/lactoperoxidase system had unique absorbance spectrum 
between 240 – 340 nm due to the formation of purines (19). In particular, hypoxanthine, 
urate and urate hydroperoxide absorbed light at 250, 290 and 310 nm. The absorbance 
spectrum for urate hydroperoxide formation was monitored with kinetic mode on the 8453 
Agilent spectrophotometer (UV visible chemstation Rev.A.10.01 [81]). The instrument was 
set to wavelength range 190 – 1100 nm, interval 1 nm and integration time 0.5 sec. Both 




Samples were made in a 1 mL quartz cuvette. The final concentrations of substances 
were: 100 µM urate, 100 µM hypoxanthine, 100 µM DTPA, 200 nM lactoperoxidase and 
approximately 1.8 µM xanthine oxidase in 50 mM phosphate buffer. As controls, 100 
µg/mL catalase and 10 µg/mL superoxide dismutase were added to quench the formation 
of urate hydroperoxide. A sample without additional urate was made to determine whether 
xanthine oxidase activity alone produced urate hydroperoxide. The spectrophotometer was 
set to measure the full spectrum (200 – 1000 nm) every 30 sec for 2000 sec. Measurements 
were made in triplicate. The absorbance spectrum was extracted for time points: 0, 120, 
240, 360, 480 and 600 sec and plotted for 240 – 340 nm. The full system absorbance at 310 
nm was extracted and plotted with time. 
 
2.2.4 Modified Ferrous Oxidation Xylenol Orange Assay for Hydroperoxides 
Hydroperoxide concentration was measured with the modified FOX assay. During 
this assay hydroperoxides oxidised ferrous to ferric iron, which formed a complex with 
xylenol orange (121). Formation of the ferric-xylenol orange complex changes the reagent 
colour from orange to brown and absorbed light at 560 nm. A modified FOX assay was 
used to measure urate hydroperoxide concentration (121). The assay samples were made 
with volume ratio 3:1 for the unknown hydroperoxide sample to FOX reagent. The 
samples were incubated for 45 min at room temperature then transferred into a 100 µL 
quartz cuvette. The Agilent spectrophotometer was set to standard mode with manual 
measurement at fixed wavelength 560 nm. The sample absorbance was compared with a 
standard curve for hydrogen peroxide to determine the hydroperoxide concentration. When 
the sample absorbance was outside the range of the linear standard curve the sample was 
diluted in phosphate buffer then reassayed. Hydroperoxide concentration was plotted 
against substance or concentration. 
 
2.2.4.1 FOX Standard Curve with Hydrogen Peroxide 
Since the concentration of urate hydroperoxide was unknown, a standard curve 
was made for the FOX assay against hydrogen peroxide. Hydrogen peroxide absorbed 
light at 240 nm, the Beer-Lambert law was used to calculate concentration its 
concentration: 




Where A = absorbance, ε = molar extinction coefficient in M
-1cm-1, c = 
concentration in M, and l = path length, 1 cm. The molar extinction coefficient of 
hydrogen peroxide was: ε(240) = 43.6 M
-1cm-1 (118). Measurement of hydrogen peroxide 
concentration was described in table 2. Hydrogen peroxide (20 µM) was diluted in 50 
mM phosphate buffer to concentrations: 0 – 5 µM. The FOX assay was performed 
(2.2.4) and plotted absorbance at 560 nm against hydrogen peroxide stock concentration. 
 
2.2.4.2 Initial Assay of Urate Hydroperoxide Formation 
The FOX assay was performed on all the substances of the xanthine 
oxidase/lactoperoxidase system to determine their interferences for later experiments. 
The substances were diluted to 300 µL in 50 mM phosphate buffer: 100 µM 
hypoxanthine, 100 µM urate, 200 nM lactoperoxidase, 0.9 µM xanthine oxidase, 100 
µg/mL catalase, 10 µg/mL superoxide dismutase and 50 mM phosphate buffer. FOX 
reagent (100 µL) was added to each sample (2.2.4). 
Next, the FOX assay was performed on xanthine oxidase/lactoperoxidase system 
after a 10 min reaction period to form urate hydroperoxide. Samples were made to 
represent the full system, removal of each substance and addition of superoxide 
dismutase as control (Appendix 2, table 6). Hypoxanthine, urate, lactoperoxidase and 
xanthine oxidase (the initiator) were mixed in phosphate buffer. The final concentration 
of substances was the same as the previous paragraph.  After 10 min incubation at room 
temperature, urate hydroperoxide production was quenched by adding 20 µg/mL 
catalase and 20 µg/mL superoxide dismutase. The samples were incubated for a further 
10 min at room temperature. The FOX reagent (102 µL) was added and the assay was 
performed (2.2.4). 
 
2.2.4.3 Optimising Urate Hydroperoxide Formation 
This experiment optimised urate hydroperoxide formation detailed in 2.2.4.2, and 
measured the resulting hydroperoxide concentration with the FOX assay. The 
concentration of urate was increased from 100 to 400 µM, and xanthine oxidase from 
0.9 to 1.8 µM. Samples (300 µL) were made to represent the old full system (2.2.4.2), 
quadruple urate, double xanthine oxidase and both (new full system). The final 




nM lactoperoxidase and 1.8 µM xanthine oxidase in phosphate buffer. After 10 min 
incubation 100 µg/mL catalase and 10 µg/mL superoxide dismutase were added to stop 
the reaction. The FOX assay was performed as described in section 2.2.4. 
 
2.2.4.4 Kinetics of Urate Hydroperoxide Formation  
This experiment used the FOX assay to measure hydroperoxide concentration 
over time for the optimised xanthine oxidase/lactoperoxidase system (2.2.4.3). The 
reaction mixture was made up to 2 mL in phosphate buffer. A control solution was made 
with the addition of 10 µg/mL superoxide dismutase. Xanthine oxidase was added last 
and the stopwatch was immediately started. At time points 0, 2, 5, 10, 15, 20, 25 and 30 
min, 220 µL of the urate hydroperoxide solution was transferred into an Eppendorf tube 
with 10 µL of 2 mg/mL catalase and 0.2 mg/mL superoxide dismutase. After 2 min 
incubation, 80 µL FOX reagent was added (2.2.4). 
Hydroperoxide concentration was plotted vs. time. To calculate the initial rate of 
urate hydroperoxide formation, the data was converted into a linear graph. The first four 
points were squared and plotted them against time. The square-root of the gradient gave 
the rate in µMmin-1. 
 
2.2.5 Statistical Analysis 
The equation and regression statistics of linear graphs were added with Excel. 
Statistical analysis of column graphs was performed with SigmaPlot for Windows version 
11.0 (Systat Systems Incorporated 2008).One-way analysis of variance (ANOVA) was 
performed to determine if the groups were significantly different. The Holm-Sidak test 
compared the significance found by ANOVA to a control. ANOVA was performed on 
replicates where the p value to reject was 0.05. Tests included the Shapiro-Wilk normality 
test (sample size 5000), Post HOC test (power, Alpha value 0.05) and the Holm-Sidak test 
vs. a control. The differences between replicates was considered significant when p<0.05. 
 
2.2.6 Graphs 
All graphs were plotted with Microsoft Excel 2013 © Microsoft Corporation 2013. 
Column graphs were made for datasets with multiple conditions/substance. Datasets where 




Error bars represented the standard deviation for multiple experiments or multiple readings. 
The number of repeat experiments performed was given in the legend. 
 
2.3 Results 
2.3.1 Superoxide Production by Xanthine Oxidase 
For this experiment I sought to optimise the superoxide generation by xanthine 
oxidase. The substrate inhibition of xanthine oxidase by hypoxanthine was determined to 
optimise superoxide production. The concentration of xanthine oxidase and hypoxanthine 
were varied in the assay cuvette and the resulting superoxide production was measured 
with the cytochrome C assay. 
 
Figure 9: Optimised superoxide production by xanthine oxidase. The cytochrome c assay was used to 
measure superoxide production. A. Superoxide production by xanthine oxidase with varying concentration of 
enzyme. The concentration of hypoxanthine was 100 µM. B. Superoxide production by xanthine oxidase 
with varying concentration of hypoxanthine. These graphs were based on one experiment. The error bars 
represent triplicate readings. 
 
Superoxide production increased with xanthine oxidase concentration and plateaued 
at approximately 10 µMmin-1 (figure 9 A). Approximately 0.2 µMmin-1 superoxide was 
produced per nM xanthine oxidase. When hypoxanthine was varied, the superoxide 
production reached a maximum of 4.5 µMmin-1 with 20 µM hypoxanthine (figure 9 B). 
Superoxide production (µMmin-1) was 0.9 per µM hypoxanthine. There was some loss of 
































































minor.  Thus, a high concentration of xanthine oxidase (1.8 µM) and hypoxanthine (100 
µM) were used for proceeding experiments since the substrate inhibition was minimal. 
 
2.3.2 Xanthine Oxidase/Lactoperoxidase System Photometry  
In this experiment I sought to visualise the formation of urate hydroperoxide and 
other products of the xanthine oxidase/lactoperoxidase system. This was achieved by 
monitoring the absorbance spectrum for the xanthine oxidase/lactoperoxidase system on a 
spectrophotometer. 
 
Figure 10: Urate hydroperoxide absorption at 310 nm over time. The absorbance at 310 nm was extracted 



























Figure 11: Absorbance of the xanthine oxidase/lactoperoxidase system. The valley at 290nm represented 
the depletion of hypoxanthine. The peaks at 290 and 310 nm was the formation of urate and urate 
hydroperoxide respectively. A. Urate hydroperoxide formation for the full enzyme system. B. Urate 
hydroperoxide formation plus catalase. C. Urate hydroperoxide formation in the absence of addition urate. 
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Urate hydroperoxide formation by xanthine oxidase and lactoperoxidase was 
visualised by monitoring multiple wavelengths on a spectrophotometer (figure 11). 
Consumption of hypoxanthine by xanthine oxidase formed a trough at 250 nm, the product 
urate formed a peak at 290 nm. The full system (figure 11 A) had a peak at approximately 
310 nm, which Patrício et al. (20) characterised to be urate hydroperoxide (ε(308) = 6,530 
M–1cm–1). Urate hydroperoxide absorbance at 310 nm peaked at approximately 15 min, 
after which the absorbance declined as the molecule degraded (figure 10). Addition of 
catalase to the system eliminated the urate hydroperoxide peak (figure 11 B).  The 310 nm 
peak was also lost when urate was removed from the system (figure 11 C). Thus, urate 
hydroperoxide formation was dependent on the presence of ROS and a high concentration 
of urate. 
 
2.3.3 FOX Assay of Urate Hydroperoxide  
For these experiments I sought to determine whether the FOX assay was appropriate 
for measurement of urate hydroperoxide formed by the xanthine oxidase/lactoperoxidase 
system. Since urate hydroperoxide was of an unknown concentration, a standard curve was 
made for the FOX assay of hydrogen peroxide as a comparison (figure 32). This standard 
curve was used as reference for the urate hydroperoxide concentration. 
 
2.3.3.1 Initial Assay Urate Hydroperoxide Formation 
The goal of this experiment was to measure the hydroperoxide concentration 
formed by the xanthine oxidase/lactoperoxidase system and whether optimisation was 
required. The FOX assay was used to measure hydroperoxide concentration through 
absorbance at 560 nm. The substances of the xanthine oxidase/lactoperoxidase system 





Figure 12: Urate hydroperoxide formed by the xanthine oxidase/lactoperoxidase system. The full 
system, removal of each substance or addition of superoxide dismutase as a quencher were assayed. The red 
line represented the baseline absorbance for the substances of the xanthine oxidase/lactoperoxidase system. 
This graph was representative of three experiments. The error bars represented the standard deviation for 
triplicate readings of one experiment. One-way ANOVA followed by Holm-Sidak multiple comparison on 
triplicate readings was used to identify samples that were significantly different from the full system (* p 
<0.05). 
 
The full xanthine oxidase/lactoperoxidase system formed approximately 4 µM 
hydroperoxide (figure 12). The addition of superoxide dismutase halved the 
hydroperoxide concentration. When urate was removed from the system, approximately 
2.5 µM hydroperoxide was formed due to xanthine oxidase activity. The removal of 
hypoxanthine, lactoperoxidase and xanthine oxidase formed less than 1 µM 
hydroperoxide. No urate hydroperoxide was made in the absence of these substances 
(20); hence 1 µM hydroperoxide represented the baseline for the FOX assay. A 
hydroperoxide concentration above the baseline represented formation of urate 
hydroperoxide. The baseline was variable with repeat experiments. For succeeding 
experiments the spectrophotometer was blanked with the full system minus 
hypoxanthine, with FOX reagent. This method removed interference by substances that 
were not urate hydroperoxide. A urate hydroperoxide concentration of 3 µM was not 

































2.3.3.2 Optimising Urate Hydroperoxide Formation 
I sought to optimise urate hydroperoxide formation by the xanthine 
oxidase/lactoperoxidase system by increasing the concentration of xanthine oxidase and 
urate. Samples were made to represent the old full system and new full system with 
double xanthine oxidase and quadruple the concentration of urate. The resulting 
hydroperoxide concentration was determined with the FOX assay. 
 
Figure 13: Optimising urate hydroperoxide formation (10 min reaction) by quadrupling urate and 
doubling xanthine oxidase. The new full system was composed of 100 µM hypoxanthine, 400 µM urate, 
200 nM lactoperoxidase and 1.8 µM xanthine oxidase in 50 mM phosphate buffer. Urate hydroperoxide 
formation was measured with the FOX assay. This graph was for one experiment. The error bars represented 
the standard deviation for triplicate readings. One-way ANOVA followed by Holm-Sidak multiple 
comparison on triplicate readings was used to identify samples that were significantly different from the old 
full system (* p <0.05). 
 
Doubling the concentration of xanthine oxidase doubled the hydroperoxide 
concentration compared with the old full system (figure 13). Quadrupling the 
concentration of urate did not affect hydroperoxide concentration. The new reaction 
system produced approximately 6.5 µM urate hydroperoxide for a 10 min reaction. 400 
µM urate was chosen for the optimised reaction system because it models the 
concentration of urate in serum during hyperuricemia. The concentration of 
lactoperoxidase and urate were varied with measurements of hydroperoxide 
concentration over time but there was no significant difference. The system was 
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2.3.3.3 Kinetics of Urate Hydroperoxide Formation 
The purpose of this experiment was to measure the formation of urate 
hydroperoxide over time with and without the presence of superoxide dismutase. At five 
min intervals urate hydroperoxide solution was transferred into an Eppendorf with 
catalase and superoxide dismutase. The reaction stopped was stopped at the 
hydroperoxide concentration was measured with the FOX assay. 
 
Figure 14: Kinetics of urate hydroperoxide formation measured with the FOX assay. At each time point, 
220 µL of the reaction mixture was transferred into a cuvette with catalase and superoxide dismutase and 
performed the FOX assay. A reaction mixture with superoxide dismutase was also made and the same method 
was used to measure hydroperoxide concentration. This graph was the mean of three experiments. The error 
bars represented the standard deviation for three experiments. 
 
The urate hydroperoxide concentration peaked at > 15 µM at 20 min (figure 14). 
The initial rate of urate hydroperoxide formation was approximately 3.2 µMmin-1. The 
maximum concentration of urate hydroperoxide formed and its subsequent degradation 
was variable between batches. When superoxide dismutase was added the 
hydroperoxide concentration remained constant at approximately 3 µM. This result 
supports that urate hydroperoxide was formed since it was superoxide-dependent. 
Future experiments used: 100 µM hypoxanthine, 400µM urate, 200 nM lactoperoxidase 
and 1.8 µM xanthine oxidase in 50 mM phosphate buffer with 20 min incubation. The 





























I successfully formed urate hydroperoxide with xanthine oxidase, lactoperoxidase 
and their substrates. Urate hydroperoxide formation was optimised by using a high 
concentration of hypoxanthine, xanthine oxidase and urate. I choose 100 µM hypoxanthine 
because the substrate inhibition of xanthine oxidase was minimal and this concentration 
had a high rate of superoxide. A high concentration of xanthine oxidase (1.8 µM) was used 
for the same reason. Increasing the concentration of urate > 100 µM did not affect urate 
hydroperoxide formation, but I choose to use 400 µM of this substance to match 
hyperuricemia. My optimised system formed > 15 µM urate hydroperoxide in 20 min. 
The FOX assay was used to determine urate hydroperoxide concentration. I assumed 
that urate hydroperoxide oxidized Fe2+ at the same ratio as H2O2, and work by Patrício et al. 
(20) supports this assumption. The concentration of urate hydroperoxide was measured 
with iodine redox titration and the FOX assay and were found to be identical. Thus, the 
FOX assay accurately measures urate hydroperoxide concentration (20). Urate 
hydroperoxide concentration could not be measured  photometrically because the xanthine 
oxidase/lactoperoxidase system produced many purine products, such as xanthine, urate 
and urate hydroperoxide, with overlapping spectrums at 310 nm (figure 11 A). Patrício et 
al. (20) calculated the extinction coefficient through riboflavin photooxidation, where the 
concentration of urate was constant and did not interfere. 
Urate hydroperoxide was not an easy substance to form and use. The concentration 
of this oxidant was variable between batches and must be used immediately because it 
degrades quickly. Measurement of urate hydroperoxide with FOX assay, which requires 45 
min to develop, hindered later experiments. The exact concentration of urate 
hydroperoxide was not known as I studied its reactivity. Thus, the concentration of urate 
hydroperoxide used to treat thiols in later chapters was not normalised. For future 
experiments, I hope to have the equipment to form urate hydroperoxide from 






Chapter 3. Urate Hydroperoxide and Reduced Thiols 
3.1 Introduction 
Urate hydroperoxide depletion of thiols could be a secondary mechanism by which 
this oxidant promotes oxidative stress and inflammation. Thiols, also known as sulfhydryls, 
are essential functional groups for a range of reactions. The most important thiols in 
biology are cysteine and glutathione, which are responsible for building biomolecules and 
antioxidant protection (21, 24). Depletion or deficiency of these thiols is associated with 
cancer, sepsis, aging, impaired HIV survival, pulmonary and neurodegenerative disease (22, 
122-125). In terms of inflammatory disease, lack of thiols exposes cells to oxidative stress 
and aggravates inflammation (126). This chapter explores the oxidation of cysteine and 
glutathione by urate hydroperoxide and discusses the implications for inflammation. 
Cysteine, a thiol amino acid, is essential for protein structure and function. Two 
cysteine residues can form a disulfide bond to join secondary structure or monomers of 
proteins (24, 127). Cysteine is chemically diverse to enable enzyme catalysis. This thiol is 
capable of acting as a nucleophile and metal ion, proton, hydride and oxygen atom transfer 
(24). ATPase, protein tyrosine phosphatase and glycolytic enzymes use cysteine residues 
for catalysis (128). Cysteine is also a precursor for glutathione, coenzyme A and hydrogen 
sulfide synthesis (127). This thiol has antioxidant activity, though this is predominantly 
expressed through glutathione (129, 130). Depletion of cysteine will prevent synthesis of 
key biomolecules required for cell survival (127). 
Glutathione, a thiol containing tripeptide, functions in protein and DNA synthesis, 
cell proliferation, reduction reactions, regulation of thiol-dependant enzymes, conjugation 
to toxins and antioxidant protection (21, 22). This thiol can scavenge hydroxyls, peroxyls 
and secondary radicals like hydroperoxides, dehydroascorbate and oxidized thiols (131). 
Glutathione’s thiol bond is facile, thus it can donate a hydride to form a sulfur-centred 
radical, or a carbon-centred radical with hydroxyl radicals. The radicals dimerise via a 
disulfide bond to glutathione disulfide (21). Glutathione disulfide is only reduced by 
glutathione reductase, which poorly replenishes glutathione during oxidative stress (22). 
Loss of this antioxidant affects many metabolic pathways. Glutathione depletion promotes 
lipid peroxidation, DNA fragmentation, increased intracellular calcium and loss of 
antioxidant and conjugation capacity (21, 132-135). On a cellular scale, glutathione 





Figure 15: Consequences of glutathione depletion for a cell. Poor diet, toxins, radiation, traumatic burns 
and infection perpetuate oxidative stress. Oxidative stress depletes antioxidants like glutathione. Loss of 
antioxidant balance (homeostasis) leads to cell functional and structural breakdown and death. Figure adapted 
from: (136). 
 
Patrício et al. (20) found that urate hydroperoxide oxidized glutathione at a 2:1 ratio 
with second order rate constant k = 13.7 ± 0.8 M-1s-1.Urate hydroperoxide did not form an 
adduct with either cysteine or glutathione. The aim of this chapter was to repeat these 
results for the oxidation of cysteine and glutathione. If urate hydroperoxide is formed at an 
inflammatory site, then I hypothesize it will oxidatively deplete cysteine and glutathione. 
The 5, 5’-dithiobis-(2-nitrobenzoic acid) (DTNB)/Ellman’s assay will be used to quantify 
thiol oxidation by urate hydroperoxide and determine the stoichiometry.  Depletion of 
cysteine and glutathione in vivo will have severe consequences for a cells antioxidant 
protection, enzyme catalysis and biomolecule synthesis (21, 24, 127). These implications 
could be a mechanism by which hyperuricemia leads to tissue damage during 
inflammatory disease.  
I compared the effectiveness of urate hydroperoxide with fellow neutrophil oxidant 
taurine chloramine. Taurine chloramine is formed when hydrogen peroxide formed during 
neutrophil oxidative burst combines with amino acid taurine (140, 141). This oxidant is 
routinely used in our lab. Peskin and Winterbourn (142, 143) characterised taurine 






3.2 Materials and Methods 
3.2.1 Materials 
Substances and solutions used throughout experimental work were put in table 3.  
 
Table 3: Description of substances and solutions used to perform the DTNB assay and prepare taurine 
chloramine and thiols. The preparation and company sourced were described. Buffers were autoclaved 
before use. 
Substance Preparation Company 
Acetic acid 100% glacial AnalaR, B10001-
78 
Bleach The concentration was approximately 500 mM. Janola premium 
bleach 
Catalase-treated phosphate buffer Phosphate buffer (50 mM) was treated with 10 
µg/mL catalase. 
 
Cysteine hydrochloride Stock of 1 mM dissolved fresh in phosphate 
buffer. 
Sigma, 7477 
L-Cystine Stock of 1 mM dissolved fresh in phosphate 
buffer. 
Sigma, C8755 
Dimethylformamide (DMF) Transfer of acid was made with glass pipette. J.T. Baker, 9221-
06 
DTNB Reagent DTNB was dissolved in phosphate buffer at 10 
mM and ultrasonicated for 2 min. Stored in dark 
and made fresh. ε(412) = 14,100 M-1cm-1 (144). 
Sigma, D8130 
Glutathione Stock of 1 mM dissolved fresh in phosphate 
buffer 
Sigma, G4251 
Glutathione disulfide Stock of 1 mM dissolved fresh in phosphate 
buffer 
Sigma, G9027 
Potassium iodide Stock of 10 mM dissolved in MilliQ. J.T. Baker, 3165 
Sodium acetate Stock of 400 mM dissolved in MilliQ, pH 
adjusted to 5.4 with acetic acid. 
BHD, 102364Q 
Taurine 10 mM dissolved in phosphate buffer, made 
fresh. 
Sigma, T0625 
Taurine Chloramine Taurine (10 mM in phosphate buffer) and bleach 
were mixed at 10:1 molar ratio (142). Taurine 




Stock of 20 mM dissolved in 100% DMF.  Fluka, 87748 
TMB Reagent Stock of 2 mM TMB/DMF (row above) diluted 
in 100 µM potassium iodide and 400 mM 
sodium acetate buffer. This reagent was kept in 
the dark and made fresh every week. 
 
Urate hydroperoxide formed by 
the xanthine 
oxidase/lactoperoxidase system 
In 50 mM phosphate buffer: 100 µM 
hypoxanthine, 400 µM urate, 200 nM 
lactoperoxidase and 1.8 µM xanthine oxidase. 
After 20 min the reaction was stopped with 100 
µg/mL catalase and 10 µg/mL superoxide 
dismutase. This solution was used immediately 
quantified with the FOX assay and used for 
experiments. 
 
Urate hydroperoxide control 
solution 
This was the xanthine oxidase/lactoperoxidase 
system without hypoxanthine. In phosphate 
buffer: 400 µM urate, 200 nM lactoperoxidase, 
1.8 µM xanthine oxidase, 100 µg/mL catalase 





3.2.2 TMB Measurement of Taurine Chloramine  
The TMB assay was used to quantify taurine chloramine (145). During this assay, 
chloramines oxidized colourless TMB to a blue product, which was photometrically 
measured at 645 nm. This reaction was catalysed by iodine. In a quartz cuvette, 20 µL of 
taurine chloramine solution (table 3) was diluted to 800 µL with phosphate buffer and was 
treated with 200 µL TMB reagent (table 3). The cuvette was incubated for 5 min then the 
absorbance was read at 645 nm on the Agilent spectrophotometer on standard mode. The 
concentration of taurine chloramine was determined with the Beer-Lambert law where: 
ε(645) = 30,000 M
-1cm-1 (145). Taurine chloramine was diluted to 20 µM with phosphate 
buffer to be used experimentally. 
 
3.2.3 DTNB Assay for Reduced Thiols 
The DTNB assay was used to quantify reduced thiols. Colourless DTNB was 
reduced by reduced thiols to yellow thionitrobenzoate (TNB), which absorbs light at 412 
nm (144). For the assay, 10 – 100 µM reduced thiol was transferred into a 1 mL plastic 
cuvette and was treated with 20 µM of 10 mM DTNB. Samples were made in triplicate. 
The cuvettes were incubated in the dark at room temperature for 10 min. The Agilent 
spectrophotometer was set to standard mode with manual measurement of fixed 
wavelength 412 nm. The spectrophotometer was blanked with 50 mM phosphate buffer 
and DTNB reagent before sample absorbance was read at 412 nm. The reduced thiol 
concentration was calculated with the DTNB extinction: ε(412) = 14,100 M
-1cm-1 (144). 
Experiments with exposure of thiols to oxidants were performed with a discontinuous 
system, wherein the thiols and oxidants were prepared separately then combined. Thiols 
were diluted with phosphate buffer when the absorbance was above 1. Reduced thiol 
concentration was plotted against substance or concentration of oxidant.  
 
3.2.3.1 Standard Curve and Controls 
Standard curves were made for the DTNB assay of cysteine, glutathione, cystine 
and glutathione disulfide to determine the linearity and specificity of the assay for 
reduced thiols. A stock of 1 mM of the thiols was transferred into plastic cuvettes to 




phosphate buffer and the DTNB assay was performed (3.2.3). Absorbance at 412 nm 
was plotted vs. thiol concentration. 
The DTNB assay was performed on the substances of the xanthine 
oxidase/lactoperoxidase system to determine their interference for later experiments. In 
plastic cuvettes, each substance was diluted to 980 µL with phosphate buffer. The final 
concentrations: 50 mM phosphate buffer, 78 µM hypoxanthine, 195 µM urate, 156 nM 
lactoperoxidase, 1.4 µM xanthine oxidase, 78 µg/mL catalase and 7.8 µg/mL superoxide 
dismutase. The substances of the xanthine oxidase/lactoperoxidase system were also 
transferred (780 µL) into plastic cuvettes with 200 µL of 350 µM cysteine or 150 µM 
glutathione. The DTNB assay was performed as previously described (3.2.3). The final 
concentration of substances was the same as section 3.2.3.2. 
 
3.2.3.2 Depletion or Cysteine and Glutathione by Urate Hydroperoxide 
Cysteine and glutathione were treated with urate hydroperoxide in a discontinuous 
system and the resulting reduced thiol concentration was measured with the DTNB 
assay. Samples were made for the xanthine oxidase/lactoperoxidase system with 
controls where each substance was removed or the addition of catalase and superoxide 
dismutase (Appendix 2, table 7). In these samples, urate hydroperoxide was allowed 20 
min to form then catalase and superoxide dismutase were added to stop the reaction. 
Immediately after the reaction was stopped 780 µL of each sample was transferred into 
plastic cuvettes with 70 µM cysteine or 30 µM glutathione in triplicate. Cysteine and 
glutathione were diluted in 780 µL phosphate buffer to determine the untreated reduced 
thiol concentration. The DTNB assay was performed (3.2.3). The hydroperoxide 
concentrations of the xanthine oxidase/lactoperoxidase system samples were determined 
with FOX assay (2.2.4). 
 
3.2.3.3 Dose-Dependent Depletion of Cysteine and Glutathione by Oxidants 
The DTNB assay was performed on cysteine and glutathione treated with varying 
concentrations of taurine chloramine or urate hydroperoxide to determine the 
stoichiometry of reduced thiol depletion. Stock cysteine (125 µM) or glutathione (75 
µM) were transferred into a plastic cuvette at 200 µL. The reduced thiols were then 




experiment was also performed with urate hydroperoxide (2.3.3.3). Glutathione (200 µL 
of 150 µM) was dose-dependently treated with 12 µM urate hydroperoxide (Appendix 2, 
table 9). To account for interference by lactoperoxidase, a control solution was made 
with all the substances except hypoxanthine. The volume of the samples were equalled 
at 980 µL with phosphate buffer. The final concentrations of oxidants were 0 – 16 µM 
taurine chloramine and 0 – 9 µM urate hydroperoxide. Stock oxidant concentration was 
checked with the TMB (3.2.2) and FOX assay (2.2.3). The cuvettes were incubated for 
10 min at room temperature and assayed with DTNB (3.2.3).  
 
3.3 Results 
3.3.1 DTNB Assay  
I wanted to use the DTNB assay to quantify reduced thiol concentration and 
depletion with exposure to oxidants. A discontinuous system was used to treat cysteine and 
glutathione with oxidants. A standard curve was made for cysteine, glutathione, cystine and 
glutathione disulfide absorbance during the DTNB assay (Appendix 1, figure 34 A). 
Cysteine and glutathione linearly absorbed light at 412 nm, whereas the absorbance of the 
oxidized forms was negligible. Thus, the DTNB assay was exclusive to reduced form of 
these thiols. The reduced thiols were exposed to the individual substances of the xanthine 
oxidase/lactoperoxidase system and the resulting thiol concentration was measured 
(Appendix 1, figure 34 B and 35). Urate and lactoperoxidase deplete cysteine, thus 
interfered with the assay. 
 
3.3.1.1 Reduced Thiol Depletion by Urate Hydroperoxide 
In this experiment I sought to measure the effect of urate hydroperoxide on 
cysteine and glutathione. The DTNB assay was performed on these thiols following 
treatment with samples for the xanthine oxidase/lactoperoxidase system. The urate 





Figure 16: Depletion of free thiols by urate hydroperoxide. A. Depletion of cysteine by urate 
hydroperoxide. B. Depletion of glutathione by urate hydroperoxide. The xanthine oxidase/lactoperoxidase 
system was incubated with 70 µM cysteine 30 µM glutathione for 10 min and DTNB assay was performed. 
The hydroperoxide concentration of each sample (for both cysteine and glutathione) were 0, 12, 16.3, 3.2, 5.8, 
2.8, 2.1 and 1.7 µM. Thus, when the baseline absorbance was removed, the urate hydroperoxide 
concentration of the full system was 10 µM. These graphs were representative of two experiments. The error 
bars represented the standard deviation of triplicate readings for one experiment. One-way ANOVA followed 
by Holm-Sidak multiple comparison on triplicate readings was used to identify samples that were 
significantly different from the phosphate buffer control (* p <0.05). 
 
When 70 µM cysteine was discontinuously exposed to urate hydroperoxide (full 
system) the reduced thiol concentration dropped to approximately 5 µM (figure 16 A). 
The addition of catalase and superoxide dismutase limited the reduced thiol depletion to 
approximately 30 µM. When hypoxanthine and xanthine oxidase were excluded from 















































































lactoperoxidase were excluded the reduced thiol concentration was close to the thiol 
concentration in phosphate buffer, 50 and 70 µM respectively. Thus, urate and 
lactoperoxidase depleted cysteine, as seen with the control experiment (Appendix 1, 
figure 35 A). It was clear that urate hydroperoxide (full system) depleted cysteine 
compare to the control (without hypoxanthine), however the sole effect of urate 
hydroperoxide was obscure. Dose-dependent depletion of cysteine by urate 
hydroperoxide was not performed because the interference by urate and lactoperoxidase 
were too strong and inconsistent. 
When approximately 30 µM glutathione was exposed to urate hydroperoxide the 
reduced thiol concentration dropped to approximately 7 µM (full system, figure 16 B). 
The addition of catalase and superoxide dismutase limited the depletion to 
approximately 20 µM. The control solutions without urate and xanthine oxidase had 
similar glutathione concentrations as the phosphate buffer control. There was a small 
increase in reduced thiol concentration when hypoxanthine and lactoperoxidase were 
left out of the system. This was most likely interference by catalase. Formation of urate 
hydroperoxide depleted glutathione (full system) compared to the control (without 
hypoxanthine). 
 
3.3.1.2 Dose-Dependent Depletion of Reduced Thiols by Taurine Chloramine 
I sought to determine the stoichiometry of cysteine and glutathione depletion by 
taurine chloramine. These thiols were dose-dependently exposed to taurine chloramine 
and the resulting reduced thiol concentration was measured with DTNB. Approximately 





Figure 17: Exposure of free thiols to dose-dependent taurine chloramine. A. Dose-dependent depletion 
of cysteine by taurine chloramine. B. Dose-dependent depletion of glutathione by taurine chloramine. The 
taurine chloramine treatment was varied by exposing the thiols to different volumes of a 20 µM stock. The 
absorbance of taurine chloramine at 412 nm when treated with DTNB was negligible. These graphs were 
representative of three experiments. The error bars represented the standard deviation of triplicate readings 
from one experiment. 
  
Taurine chloramine reaction with cysteine or glutathione resulted in a linear loss of 
absorbance at 412 nm as the thiols were oxidized (figure 17). The stoichiometry for the 
depletion of cysteine by taurine chloramine was 2:1, whereas glutathione depletion by 
taurine chloramine was 3:2 ratio. These ratios were close to 2:1 and imply that taurine 
chloramine dimerised reduced thiols. Thus, one taurine chloramine depleted two reduced 
thiols. These results were similar to Peskin and Winterbourn (142), who determined the 
stoichiometry of thiol oxidation to be 2.1:1 for cysteine and 1.8:1 for glutathione with 
taurine chloramine. 
 
3.3.1.3 Dose-Dependent Depletion of Glutathione by Urate Hydroperoxide 
Glutathione was exposed to urate hydroperoxide in a dose-dependent manner to 
determine the stoichiometry of its oxidation. Approximately 25 µM glutathione was 
treated with 0 – 10 µM urate hydroperoxide. The resulting thiol concentration was 
measured with the DTNB assay. 


















































Figure 18: Dose-dependent depletion of glutathione by urate hydroperoxide. Glutathione was incubated 
with increasing concentrations urate hydroperoxide. This graph was representative of two experiments. The 
error bars represented the standard deviation for triplicate readings for one experiment. 
 
Urate hydroperoxide linearly depleted glutathione (figure 18). The stoichiometry 
of glutathione oxidation by urate hydroperoxide was 2:1. This ratio was identical to 
results by Patrício et al. (20) and taurine chloramine depletion of reduced thiols (figure 
17). This ratio implies a urate hydroperoxide molecule oxidises glutathione to 
glutathione disulfide, thus depleting two reduced thiols. 
 
3.4 Discussion 
The depletion of reduced thiols by taurine chloramine and urate hydroperoxide was 
measured through loss of DTNB absorbance at 412 nm. Lactoperoxidase interfered with 
the depletion of cysteine by urate hydroperoxide, but it was apparent from Figure 16 A. 
that urate hydroperoxide oxidises this amino acid. Lactoperoxidase and urate seem to 
deplete cysteine (figure 16 A and 35 A). Cysteine could bind lactoperoxidase in the 
absence of hydrogen peroxide, then enter the peroxidase cycle to be oxidized to cystine 
(146-149). Cysteine has antioxidant properties and may scavenge oxidized urate (74). This 
result was consistent with previous work by Kuzkaya et al. (74), wherein urate’s 
antioxidant capacity was extended by the presence of cysteine to reduce the urate radical. 

























Glutathione was depleted by urate hydroperoxide at ratio 2:1. This ratio suggests 
glutathione passed a hydride to urate hydroperoxide and dimerised to glutathione disulfide. 
Thus, urate hydroperoxide did not form an adduct to the thiol. Patrício et al. (20) published 
mass spectrometry data with the same ratio for glutathione depletion by this oxidant. 
Together, this was strong evidence that urate hydroperoxide oxidises glutathione to 
glutathione disulfide. Lactoperoxidase marginally depleted glutathione, thus it was unlikely 
to enter this enzyme’s peroxidase cycle (figure 16 B and 35 B). Steric hindrance by the 
glycine and glutamate side-chains may have prevented oxidation by lactoperoxidase (150). 
Cysteine is an essential building block for biomolecules, thus urate hydroperoxide 
depletion of this molecule will affect anabolism of the cell. Dose-dependent depletion of 
cysteine by urate hydroperoxide could be performed with the riboflavin photooxidation 
system to bypasses interference by lactoperoxidase. My findings could be expanded to 
other important thiol-containing compounds such as cysteine analogue, homocysteine; or 
glutathione precursor, cysteinylglycine (151). Also, the glutathione to glutathione disulfide 
ratio could be measured for cells exposed to urate hydroperoxide. Mass spectrometry 
should be performed on cysteine and glutathione treated with urate hydroperoxide to 
confirm that this oxidant did not form an adduct to cysteine or glutathione. 
Urate hydroperoxide will deplete cysteine at inflammatory sites, hence starving the 
surrounding cells of this essential amino acid. Serum cysteine is mainly protein-bound or 
oxidized; the concentration of free cysteine is only 10 µM (151). Therefore, urate 
hydroperoxide may have a more significant effect on protein-bound cysteine used by 
enzymes for catalysis. Urate hydroperoxide formation will aggravate oxidative stress by 
depleting antioxidants like glutathione, leading to exposure of the cell to oxidants and 
toxins. However, glutathione is a minor antioxidant in blood serum and is present at 4 µM 
(151). For urate hydroperoxide to affect the glutathione pool it must be uptaken into cells 
where the concentration is up to 10 mM (152). Urate hydroperoxide is unlikely to achieve 
concentrations of 5 mM to deplete this pool, hence it must work in conjunction with other 








Chapter 4. Urate Hydroperoxide and Glyceraldehyde-3-Phosphate 
Dehydrogenase 
4.1 Introduction 
Inactivation of thiol-dependent enzymes by urate hydroperoxide could be the link 
between hyperuricemia and inflammatory disease. Enzymes that rely on a cysteine residue 
for catalysis, or thiol-dependent enzymes, are ubiquitous in biology (24). Catalytic 
cysteines are powerful soft nucleophiles with highly polarizable empty d-orbitals. They are 
often paired with a histidine residue, which lowers the pKa of cysteine from 8.3 to 2.5 – 8 
(153, 154). These attributes make catalytic cysteines vulnerable to electrophilic oxidants 
like urate hydroperoxide (154, 155). Oxidation of catalytic cysteines inactivates the 
enzyme (23, 153). Metabolic pathways affected by thiol-dependent enzyme inactivation 
include glycolysis, electron transport, oxidative signalling and glutathione metabolism. 
These pathways are essential for cell function, therefore cell survival may be affected by 
electrophilic oxidants (24). The aim of this chapter is to determine whether urate 
hydroperoxide inactivates a thiol-dependent enzyme and the resulting modification. I used 
GAPDH as a model for thiol-dependent enzymes. 
GAPDH catalyses the sixth step of glycolysis and is essential for the function of all 
cells (29). This enzyme also functions in cell proliferation, oxidative signalling, apoptosis, 
membrane transport, cytoskeleton dynamics, DNA replication and repair (29, 156, 157). 
GAPDH catalyses the addition of an inorganic phosphate to GAP using cofactor oxidized 
nicotinamide adenine dinucleotide (NAD+), the products are 1,3-bisphosphoglycerate 
(BPG) and reduced nicotinamide adenine dinucleotide (NADH). The mechanism for 
catalysis is hydride transfer from GAP to NAD+, in which the catalytic cysteine (Cys149) 
forms a covalent bond to GAP (158-162) (figure 19). GAPDH inactivation uncouples 
oxidation and phosphorylation during glycolysis, preventing the production of ATP and 
leading to cell death (27, 163). Loss of function for this enzyme has repercussions for 





Figure 19: Crystal structure and active site configuration of rabbit muscle GAPDH. This enzyme is a 
homotetramer with the active site is a NAD-binding Rossman fold domain. The essential cysteine is 
positioned to covalently bind GAP. His176 transfers a hydride from the intermediate to NAD+, producing 
NADH. Figure adapted from (28). 
 
The essential GAPDH thiol can undergo a number of modifications, following 
oxidant exposure, resulting in inactivation (figure 20). Cys149 is consecutively oxidized to 
sulfenic, sulfinic and sulfonic acid. Sulfenic acid is highly reactive and forms a disulfide 
bond between Cys149 and Cys153 in rabbit muscle GAPDH, or mixed a disulfide bond 
with other thiol molecules (27, 143). Though, it is debatable whether Cys149 and Cys153 
are close enough to form a disulfide bond (27, 162). This modification is reversible with 
reduction by glutathione. Sulfinic acid is stable and is solely removed by sulfiredoxin, 
whether this occurs in vivo is unclear (164). Sulfonic acid is the final state of overoxidation 
and is essentially irreversible (23). Oxidants and alkylating agents form adducts to Cys149, 









Figure 20: Modifications of the GAPDH essential thiol formed during inactivation by oxidants. Cys149 
can form a disulfide bond with an adjacent cysteine reside (Cys153). This modification is made by taurine 
chloramine and is reversible by dithiothreitol (DTT)/glutathione. Cys149 can be overoxidized to sulfenic, 
sulfinic or sulfonic acid. Formation of sulfonic acid is irreversible in vivo. Oxidants or alkylating agents can 
form irreversible adducts to Cys149. Figure adapted from (27). 
 
Urate hydroperoxide inactivation of thiol-dependent enzymes may link 
hyperuricemia and tissue damage during inflammatory disease. I hypothesize that urate 
hydroperoxide inactivates the thiol-dependent enzyme GAPDH and oxidises its cysteine 
residues. My basis for this hypothesis is that electrophilic oxidants induce modifications to 
thiol-dependent enzymes (24). As a hydroperoxide, urate hydroperoxide is a highly 
reactive oxidant (20). GAPDH was chosen as a model for thiol-dependent enzymes 
because it is an abundant and essential enzyme in all cells. I aim to determine the 
concentration of urate hydroperoxide that was required to inactivate GAPDH, whether 























4.2 Materials and Methods 
4.2.1 Materials 
Substances and solutions used throughout experimental work were put in table 4.  
 
Table 4: Description of substances and solutions used to perform the GAPDH assay, gel electrophoresis 
and mass spectrometry. The preparation and company sourced were described. Buffers were autoclaved 
before use.  
Substance Preparation Company 
4% Acrylamide stacking gel In MilliQ: 4% Acrylamide/bis, 0.6 M Tris 
HCl (pH 8.8), 0.1% SDS, 0.05% APS and 
0.16% TEMED. 
 
15% Acrylamide resolving gel In 0.6 M Tris HCl (pH 8.8): 25% 
Acrylamide/bis, 0.15% SDS, 0.08% APS, 
0.2% TEMED. 
 
40% Acrylamide/bis solution Acrylamide to Bis = 37.5:15 BioRad, 1610148 
Ammonium persulfate (APS) Stock of 10% (w/v) dissolved in MilliQ. Sigma, A3678 
Ammonium Bicarbonate   
Bio-gel polyacrylamide beads Bio-gel P-6DG desalting gel, 990-180 µM. BioRad, 150-0738 
Bromophenol blue  Sigma, B1131 
DL-dithiothreitol (DTT) 0.1 M was dissolved in 50 mM phosphate 
buffer. For SDS-PAGE used 1 M DTT. 
Sigma, D9779 
Electrode buffer In MilliQ: 25 mM Tris, 192 mM glycine, 
0.1% SDS, pH adjusted to 8.3. 
 
Formic acid  Merck, 1.00263.100 
GAP Diluted from 45 mg/mL to 10 mM in 
phosphate buffer. 
Sigma, G-5251 
Glycerol  Sigma, G5516 
Glycine (Gly)  Sigma, G8898 
β-mercaptoethanol  Sigma, 63699 
NAD+ Stock of 10 mM dissolved in phosphate 
buffer. 
Sigma, N-7004 
NADH Stock of 1 mM dissolved in phosphate 
buffer. 
Sigma, N8129 
Protein Standard Dual Colour Protein ladder for SDS-PAGE. Precision Plus, 
#16103744110029 
Rabbit Muscle GAPDH Dissolved in 50 mM TEA buffer, ε(280) = 
149 mM-1cm-1 (166). 
ICN Biomedical Inc., 
[9001-50-7] 
Sodium dodecyl sulfate (SDS)  Fisher Science, 
SP53053 
Solvent A (mobile phase) In MilliQ: 0.1% formic acid  
Solvent B (mobile phase) In acetonitrile: 0.1% formic acid  
Tetramethylethylenediamine 
(TEMED) 
 Sigma, T9281 
Triethanolamine (TEA)   BDH, 103704U 
TEA buffer In MilliQ: 50 mM TEA and 50 mM 





 Roche, 10708976001 
Sample Buffer for sodium dodecyl 
sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE) 
In MilliQ: 60 mM Tris-HCl (pH 6.8), 20% 
(v/v) glycerol, 2% (v/v) SDS, 5% (v/v) β-






4.2.2 GAPDH Assay  
The GAPDH assay was used to assess the enzymes activity after various treatments. 
This assay exposed GAPDH to its substrates and measured the formation of NADH at 340 
nm. This method was optimised from Seidler (167). The assay was performed with a 
Hitachi spectrophotometer and 1 mL quartz cuvette. The spectrophotometer was set to 
measure -0.1 – 1 absorbance at 340 nm for 300 sec, spectral band width = 2 at 25ºC. The 
assay required approximately 60 nM GAPDH, 0.5 mM GAP, 1 mM NAD+ and 50 µM 
DTPA, dissolved in 1 mL TEA buffer. The spectrophotometer was blanked with all 
substances except GAPDH, which initiated the assay. The initial rate of GAPDH activity 
was calculated as A.min-1 over 10 – 50 sec. GAPDH activity was expressed as a percent by 
designating GAPDH diluted in phosphate buffer as 100% activity. Graphs were plotted for 
GAPDH activity (%) vs. substance or concentration of oxidant. 
 
4.2.2.1 Optimising the GAPDH Assay 
The concentration of NAD+ and DTT used during the GAPDH assay was 
optimised to achieve high activity (A.min-1). GAPDH activity was assayed over a 
number of concentrations of NAD+ to determine the saturation concentration for this 
substrate. The concentration of NAD+ was varied by diluting a10 mM stock of in 
phosphate buffer to make a dilution series. Each dilution (100 µL) was transferred into 
the assay cuvette (with 2 mM DTT) to achieve final concentrations 0 – 1.4 µM.  Next 
the concentration of DTT required to activate the enzyme was determined. The 
concentration of DTT was high enough to reduce the enzyme yet easily removed with 
spin columns. Stock DTT (100 mM) was added at different volumes to the assay cuvette 
to achieve final concentrations 0 – 7.5 mM. The other substances of the assay were 
diluted in TEA buffer and the assay was performed (4.2.2).  
The linearity of GAPDH activity with concentration was determined by creating a 
standard curve. GAPDH (25 µM) was diluted in TEA buffer. The concentration of 
GAPDH in the cuvette was 0 – 400 nM. 
 
4.2.2.2 Preparation of Reduced GAPDH with Spin Columns 
GAPDH was isolated from DTT with spin columns to allow treatment of the 




30 min. Mini-Bio-Spin® chromatography columns were prepared by adding 700 µL wet 
Bio-Gel polyacrylamide and allowing excess liquid to flow through. Columns were 
washed four times with MilliQ and once with TEA buffer. The columns were packed by 
centrifugation at 1000 g for 2 min. GAPDH and DTT samples were injected on top of 
each column at a maximum volume of 75 µL. The columns were centrifuged at 1000 g 
for 4 min to elute GAPDH.  
The effectiveness of spin column isolation was assessed by measuring 
concentration and activity for each step of GAPDH reduction and isolation (Initial, 
addition of DTT and isolation with spin columns). The assay cuvette did not have 
additional DTT (4.2.2). 
 
4.2.3 NAD+ and NADH Photometry 
The purpose of this experiment was to determine whether taurine chloramine or urate 
hydroperoxide oxidised NAD+ or NADH, thus creating interference with the GAPDH 
assay. NAD+ absorbed light at 260 nm while NADH absorbed at  260 and 340 nm (168). 
Photometric measurement at 340 nm was used to show the formation or depletion of 
NADH. The Agilent spectrophotometer was blanked with phosphate buffer in a 1 mL 
quartz cuvette. The buffer was replaced with the NAD solution dissolved in phosphate 
buffer and triplicate readings were made. The extinction coefficients were: ε(260) = 18,000 
M-1cm-1 and ε(340) = 6,220 M
-1cm-1 (168). NAD concentration was plotted vs. concentration 
of oxidant. 
Standard curves were made for NAD+ and NADH absorbance at 260 and 340 nm. 
NAD+ or NADH (10 mM) was diluted with phosphate buffer to make a dilution series. The 
NAD dilutions (100 µL) were added to 900 µL phosphate buffer and the absorbance at 260 
and 340 nm was measured for both oxidation states. The final concentrations for NAD+ 
and NADH were 0 – 20 and 0 – 150 µM respectively. 
 
4.2.3.1 Dose-Dependent Treatment of NAD+ and NADH with Oxidants 
The oxidation state of NAD was photometrically measured following dose-
dependent treatment with oxidants. NAD+ and NADH were exposed to varying volumes 
of taurine chloramine or urate hydroperoxide and incubated for 10 min at room 




was read at 260 and 340 nm, having blanked the Agilent spectrophotometer with the 
same concentration of oxidant (4.2.3).  
In Eppendorf tubes, NAD+ (25 µL of 80 µM) was exposed to varying volumes of 
30 µM taurine chloramine and the volume was equalled at 375 µL with phosphate buffer. 
The final concentrations of taurine chloramine were 0 – 28 µM. NADH (40 µM) was 
treated with 0 – 159 µM taurine chloramine. The same method was used to dose-
dependently treat NAD with urate hydroperoxide. NAD+ (40 µL of 60 µM) and NADH 
(40 µM) were treated with varying volumes of 8 µM urate hydroperoxide (2.3.3.3). 
Samples were made up to 600 µL with phosphate buffer. The final urate hydroperoxide 
concentrations were 0 – 3.8 µM or 0 – 7 µM. Due to interference by the xanthine 
oxidase/lactoperoxidase system, only samples with the five lowest concentrations of 
urate hydroperoxide could be read.  
 
4.2.4 Continuous Inactivation of GAPDH by Urate Hydroperoxide 
The GAPDH assay was combined with the xanthine oxidase system in a quartz 
cuvette and the GAPDH activity was assayed. This was a continuous system where urate 
hydroperoxide was formed as GAPDH activity was assayed at 340 nm (4.2.2). Samples 
were made in triplicate to represent the full xanthine oxidase/lactoperoxidase system, 
removal of a substance or addition of quenchers (Appendix 2, table 10). The final 
concentration of the xanthine oxidase/lactoperoxidase system were 100 µM hypoxanthine, 
250 µM urate, 200 nM lactoperoxidase and 1.8 µM xanthine oxidase. All samples had 60 
nM GAPDH (DTT-reduced), 0.5 mM GAP, 1 mM NAD+ and 50 µM DTPA in 1 mL TEA 
buffer. The spectrophotometer was blanked before the addition of xanthine oxidase and 
GAPDH as initiators for the two systems. As a control, the substances used to assay 
GAPDH activity were diluted in TEA buffer to represent 100% GAPDH activity.  
The raw data (absorbance vs. time) for one replicate per sample was collated as a 
graph. The GAPDH activity for each triplicate was calculated for time periods: 30 – 60, 60 
– 120, 120 – 180, 180 – 240 and 240 – 360 sec. These rates were plotted at time points 45, 





4.2.5 Discontinuous Inactivation of GAPDH by Oxidants 
A discontinuous system was used to measure the inactivation of GAPDH by taurine 
chloramine or urate hydroperoxide. GAPDH and the oxidants were prepared separately and 
mixed together in Eppendorf tubes as samples. GAPDH was reduced and isolated with a 
spin column at a high concentration (10 µM) and diluted 10 times in the samples with the 
oxidant. This experimental design allowed a maximum concentration of oxidant in the 
samples whilst the GAPDH concentration was constant with measurable activity. 
 
4.2.5.1 GAPDH Inactivation by Urate Hydroperoxide 
GAPDH was treated with the substances of the xanthine oxidase/lactoperoxidase 
system and assayed for change in enzyme activity. The final concentrations were the 
same as later experiments for inactivation of GAPDH by urate hydroperoxide (next 
paragraph). Each substance of the xanthine oxidase/lactoperoxidase system was diluted 
in 180 µL phosphate buffer. The concentrations were: 100 µM hypoxanthine, 400 µM 
urate, 200 nM lactoperoxidase, 1.8 µM xanthine oxidase or 50 mM phosphate buffer. 
Next, 20 µL of 10 µM GAPDH was added to each solution. After 10 min incubation the 
GAPDH activity for each sample was measured (4.2.2). 
Xanthine oxidase/lactoperoxidase system samples (Appendix 2, table 11) were 
made in Eppendorf tubes. After 20 min incubation, having stopped the reaction with the 
quenchers, the hydroperoxide concentration was measured with the FOX assay. 
GAPDH (1 µM) was treated with 180 µL of each sample.  After 10 min incubation 
GAPDH activity was assayed. A control was made with 1 µM GAPDH diluted in 
catalase-treated phosphate buffer to represent the active enzyme. The final concentration 
of substances were approximately 80 µM hypoxanthine, 330 µM urate, 160 nM 
lactoperoxidase, 1.5 µM xanthine oxidase, 80 µg/mL catalase (160 µg/mL for G.) and 8 
µg/mL superoxide dismutase (16 µg/mL for F.). 
 
4.2.5.2 Dose-Dependent Inactivation of GAPDH by Oxidants 
The GAPDH assay was used to assess the effect of oxidants on enzyme activity. 
GAPDH (20 µl of 10 µM) was treated with a varying volume of 20 µM taurine 
chloramine or 7 µM urate hydroperoxide. Catalase-treated phosphate buffer was added 




16 µM taurine chloramine or 0 – 6 µM urate hydroperoxide (2.3.3.3). Samples were 
incubated at room temperature for 10 min and assayed for GAPDH activity (4.2.2). The 
stock concentrations of taurine chloramine and urate hydroperoxide were confirmed 
with the TMB (3.2.2) and FOX (2.2.4) assay respectively. 
 
4.2.6 Inactivation Kinetics for GAPDH  
The GAPDH assay was performed at various time points during discontinuous 
inactivation by oxidants. GAPDH was exposed to the oxidant in an Eppendorf tube and at 
set time points this solution was injected into the spectrophotometer and assayed for 
GAPDH activity. Three cuvettes were prepared in the Hitachi spectrophotometer with all 
the substances for the GAPDH assay, bar GAPDH. The spectrophotometer measured 340 
nm throughout the experiment. In an Eppendorf tube, 20 µl of 10 µM GAPDH was 
combined with 180 µL of the oxidant and the stopwatch was immediately started. At three 
given time points, 60 µL of the sample was injected into a quartz cuvette. Four samples 
were made with staggered time points. The time points for a given sample were at least 45 
sec apart to allow a linear slope to be made. Time points for samples: 
1. 10, 60, 100 sec 
2. 20, 75, 120 sec 
3. 30, 90, 170 sec 
4. 45, 140, 200 sec 
The kinetics experiment was repeated three times for each oxidant. GAPDH activity 
(%) was plotted vs. time. 
GAPDH (20 µL of 10 µM) was mixed with 180 µL of 20 µM taurine chloramine or 3 
µM urate hydroperoxide. Taurine chloramine degrades slowly at room temperature, thus its 
concentration was similar for all the time points. Urate hydroperoxide degrades quickly, 
hence each sample was made from a new urate hydroperoxide solution. This increased the 
variability in the experiment because the urate hydroperoxide concentration was not 
identical per sample.  
 
4.2.7 Reactivation of GAPDH Following Dose-Dependent Inactivation by Oxidants 
This experiment assayed the reversibility of GAPDH inactivation by oxidants by 




after inactivated GAPDH was exposed to DTT. Both samples sets were dose-dependently 
exposed to oxidants (4.2.5.2). One sample was exposed to catalase-treated phosphate 
buffer and served as a control to measure GAPDH inactivation. The second sample set was 
reduced with 2 mM DTT. All samples had a uniform concentration of substances. 
GAPDH (1 µM) was dose-dependently exposed to 20 µM taurine chloramine 
(Appendix 2, table 12) or 7 µM urate hydroperoxide (Appendix 2, table 13). After 10 min 
incubation, the samples sets were either treated with DTT (2 mM) or diluted with catalase-
treated phosphate buffer. Samples were incubated for 30 min before measuring the 
GAPDH activity. The final concentrations of oxidants were 0 – 18 µM taurine chloramine 
or 1 – 6 µM urate hydroperoxide. GAPDH was diluted in catalase-treated phosphate buffer 
and reduced with DTT to represent 100% GAPDH activity. GAPDH activity (%) was 
plotted against oxidant concentration for inactivate and reactivated samples. 
 
4.2.8 DTNB Measurement of Cysteine Residues on GAPDH 
The DTNB assay was used to measure depletion of cysteine residues on GAPDH by 
oxidants. This assay was modified to measure reduced thiol concentration in quartz 
cuvettes (162). GAPDH was reduced with DTT for 30 min and passed through spin 
columns twice to isolate GAPDH (4.2.2.2). The 380 µL samples were treated with 20 µL 
of 10 mM DTNB reagent and incubated for approximately 10 min in the dark. The Agilent 
spectrophotometer was blanked with TEA buffer treated with DTNB reagent. The assay 
solution was transferred into a 100 µL quartz cuvette and the absorbance was read at 412 
nm on an Agilent spectrophotometer as previously described (3.2.3). The reduced thiol 
concentration was calculated with the DTNB extinction coefficient and plotted against 
substance or oxidant concentration. 
A standard curve was made by varying the concentration of GAPDH exposed to 
DTNB. A stock of 1 µM GAPDH was diluted to 0 – 1200 nM with TEA buffer to make a 
dilution series. GAPDH (3 µM) was also treated with the substances of the xanthine 
oxidase/lactoperoxidase system to determine their interference with the assay. The final 
concentrations were the same as section 4.2.8.1: 50 mM phosphate buffer, 90 µM 
hypoxanthine, 360 µM urate, 190 nM lactoperoxidase, 1.7 µM xanthine oxidase, 95 µg/mL 
catalase and 9.5 µg/mL superoxide dismutase. After 10 min incubation the DTNB assay 




4.2.8.1 Dose-Dependent Depletion of Cysteine Residues on GAPDH by Oxidants 
The DTNB assay was used to measure the concentration of cysteine residues on 
GAPDH following dose-dependent exposure to oxidants (4.2.8). GAPDH (3 µM) was 
treated with varying volumes of 20 µM taurine chloramine or 9 µM urate hydroperoxide 
(2.3.3.3) discontinuously. The volume was made up to 190 µL with phosphate buffer. 
After 10 min incubation the DTNB assay was performed (4.2.8). The stock oxidant 
concentrations were determined with the TMB (3.2.2) and FOX assay (2.2.4). 
 
4.2.9 Polyacrylamide Gel Electrophoresis 
Laemmli-SDS-PAGE was performed to separate and visualise GAPDH and the 
xanthine oxidase/lactoperoxidase system (169). SDS-PAGE involved the movement of 
proteins through a polyacrylamide gel matrix with the applied electrical current. Proteins 
were separated by mass and charge, with small proteins travelling faster through the matrix. 
SDS, an anionic detergent, was used to promote the movement of the protein with the 
charge. Proteins were treated with coomassie brilliant blue, which stains proteins blue 
(170). 
Two stacking gels were made from a 15% acrylamide resolving gel and 4% stacking 
gel. The composition of the gels was given in table 4. The resolving gel was poured first 
and was dried at room temperature for 20 min. The stacking gel was poured on top and 
wells were created with a comb. The following samples were made to 100 µM using a 
discontinuous system as previously described. The final concentration of substances were 
1.5 µM GAPDH and 0 – 10.5 µM urate hydroperoxide (2.3.3.3). 
1. Protein marker (Precision Plus protein standards dual colour) 
2. GAPDH 
3. Urate hydroperoxide 
4. 1:1 GAPDH and urate hydroperoxide 
5. 2:7 GAPDH and urate hydroperoxide 
6. 1:7 GAPDH and urate hydroperoxide  
For the non-reducing gel, 20 µL of each sample was transferred into an Eppendorf 
tube with 2.5 µL phosphate buffer and 5 µL non-reducing sample buffer. For the reducing 
gel, the phosphate buffer was replaced with 2.5 µL of 1 M DTT. Samples (28 µL) were 




sample 3, well 7 – sample 4 and well 8 – sample 5. The protein marker Precision Plus 
protein Standards Dual Colour was injected (3 µM) into well 3. The gel tanks were filled 
with Tris-Gly, pH 8.3 electrode buffer and ran for 60 min at 200 V. A BioRad gel dock 
(universal hood 11-S.N.765/00260) was used to visualise the protein. Documentation was 
performed with Quality One Chemidoc XRS (version 4.6.1.build 05). The gels where 
exposed to light for 500 sec and an image was taken. 
 
4.2.10  GAPDH Mass Spectrometry 
Whole protein mass spectrometry was performed on samples of GAPDH treated with 
urate hydroperoxide (2.3.3.3) and/or DTT in a discontinuous system. This method allowed 
identification of molecular weight changes to the GAPDH monomer with treatments. 
Proteins entered the mass spectrometer from the high performance liquid chromatography 
(HPLC) column. Electrospray ionisation applied a high voltage and temperature to the 
protein to form an ionised aerosol. This method minimised fragmentation of the proteins. 
The ionised proteins were separated based on their mass-to-charge (m/z) ratio by the 
quadrupole ion trap and were sent to the detector (171). Molecular weight was calculated 
from m/z and charge of the ionised protein: 
 
Where: m/z = mass-to-charge ratio, m = mass (Da), H+ = mass of hydrogen (1.008 
Da) and n = number of charges. GAPDH (4.2 µM) was incubated with urate hydroperoxide 
(3.5 µM) (2.3.3.3) for 10 min. Samples were then treated with 2 mM DTT for 30 min or 
were diluted with phosphate buffer. The final volume was 100 µL: 
A. GAPDH 
B. GAPDH and DTT 
C. GAPDH and urate hydroperoxide  
D. GAPDH, urate hydroperoxide and DTT  
The Velos Pro ion-trap mass spectrometer (Thermo Scientific) was set to positive ion 
mode. The resulting mass spectrums were deconvoluted with ProMass for Xcalibur. The 







4.3.1 Optimising the GAPDH Assay 
In these experiments I wanted to optimise the GAPDH assay to allow assessment of 
GAPDH activity after oxidant treatments. The concentration of NAD+ and DTT were 
varied from 0 – 1.4 µM and 0 – 7.5 mM respectively in the assay cuvette. The resulting 
GAPDH activity was measured at 340 nm. 
  
Figure 21: Optimising the GAPDH assay. A. Optimising the NAD+ concentration used for the GAPDH 
assay. The concentration of NAD+ was varied in the cuvette during the GAPDH assay. The concentrations for 
all other substances were constant for the assay. B. Optimising the DTT concentration used for the GAPDH 
assay. The concentration of DTT was varied in the cuvette during the GAPDH assay. The concentrations for 
all other substances were constant. These graphs represented two experiments. 
 
During NAD+ optimisation, GAPDH activity reached a maximum of 0.08 A.min-1 at 
1 mM NAD+, after which the activity plateaued (figure 21 A). The addition of DTT to the 
assay cuvette dramatically increased the GAPDH activity (figure 21 B). The enzyme 
activity reached a maximum at 1 mM DTT, at a rate six times greater than in the absence of 
DTT. There was some loss of GAPDH activity with DTT concentrations > 1 mM, but the 
activity was still high. Based on these results, GAPDH was reduced with 2 mM DTT and 
isolated with spin columns. GAPDH was assayed with 1 mM NAD+. The optimised 
GAPDH assay used concentrations: 60 nM GAPDH (reduced with 2 mM DTT), 0.5 mM 
GAP, 1 mM NAD+ and 50 µM DTPA in TEA buffer. 
A series of experiments were preformed to assess the interference of the xanthine 






















































concentration in the presence of DTT (Appendix 1, figure 36). This enzyme was isolated 
from DTT with spin columns with a workable concentration and activity (Appendix 1, 
figure 37). NAD absorbance at 260 and 340 nm was used to assess the oxidation state 
(Appendix 1, figure 38). Exposure of this cofactor to taurine chloramine and urate 
hydroperoxide did not affect the oxidation state at concentrations used for GAPDH 
inactivation assay (Appendix 1, figure 39 and 40).  
 
4.3.2 GAPDH Inactivation by Continuous Urate Hydroperoxide Formation 
In this experiment I sought to measure the effect of urate hydroperoxide on GAPDH 
as it was formed by the xanthine oxidase/lactoperoxidase system. In a quartz cuvette the 
GAPDH assay and the xanthine oxidase/lactoperoxidase systems were mixed in TEA 
buffer. The absorbance at 340 nm was monitored. None of the substances used to make 
















Figure 22: GAPDH inactivation during continuous formation of urate hydroperoxide. The substances of 
the GAPDH assay and xanthine oxidase/lactoperoxidase system were mixed in a quartz cuvette. Xanthine 
oxidase and GAPDH were the initiators. Each sample represented the removal of a substance from the 
xanthine oxidase/lactoperoxidase system or addition of catalase and superoxide dismutase. The control ‘TEA 
buffer’ only had the substances for the GAPDH assay to represent 100% GAPDH activity. Top: Raw data of 
each sample’s absorbance at 340 nm. Bottom: GAPDH activity vs. time for each sample expressed as a 
percent. These graphs represented one experiment and the error bars were standard deviation for triplicate 
readings. 
 
Figure 22 illustrates how the xanthine oxidase/lactoperoxidase system in situ effects 
GAPDH activity. Compared with the TEA buffer control, the full system had a 
significantly lower maximum absorbance (figure 22 A). The addition of superoxide 
dismutase was not effective in increasing the maximum absorbance, whereas the addition 
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lactoperoxidase and xanthine oxidase) had similar absorbance to TEA buffer. When the 
GAPDH activity was converted into a percent, the effect of urate hydroperoxide formation 
became distinct (figure 22 B). Initially, the full system caused a 40% loss of activity, this 
increased to approximately 70% in 4 min. During this time period approximately 5 µM 
urate hydroperoxide was made (figure 14). The addition of superoxide dismutase did not 
prevent the inactivation of GAPDH. All other samples had similar GAPDH activities.  
The loss of GAPDH activity with the full xanthine oxidase/lactoperoxidase system 
implies a urate oxidant was responsible. Urate hydroperoxide was not solely responsible 
for inactivation of GAPDH since other oxidants were formed. Next, a discontinuous 
system was used to determine inactivation of GAPDH by urate hydroperoxide. The 
advantage of this system was that urate hydroperoxide dominated the oxidants formed. 
 
4.3.3 Discontinuous Inactivation of GAPDH 
4.3.3.1 Inactivation of GAPDH by Urate Hydroperoxide 
For this experiment, I sought to determine whether the xanthine 
oxidase/lactoperoxidase system effected GAPDH activity. GAPDH was discontinuously 
exposed to samples for this system and the enzyme activity was assayed. The urate 
hydroperoxide concentration for the full system was 5 µM. 
 
Figure 23: Inactivation of GAPDH by urate hydroperoxide. GAPDH was treated with samples for the 
xanthine oxidase/lactoperoxidase system. These samples included the full system, removal of a substance or 
addition of catalase or superoxide dismutase. The hydroperoxide concentrations for samples A – G were 5, 
2.7, 3.6, 0.9, 0.3, 0.1 and 0.2 µM. This graph was representative of two experiments. The error bars 
represented the standard deviation of triplicate readings for one experiment. One-way ANOVA followed by 
Holm-Sidak multiple comparison on triplicate readings was used to identify samples that were significantly 






































GAPDH was treated with the xanthine oxidase system to determine the effect of 
urate hydroperoxide on enzyme activity (figure 23). The full system with 5 µM urate 
hydroperoxide caused a 60% loss of GAPDH activity. The addition of catalase to the 
xanthine oxidase/lactoperoxidase system did not prevent GAPDH inactivation, whereas 
superoxide dismutase minimised the loss of activity to 20%. Hence, superoxide was 
essential for oxidant formation and GAPDH inactivation. When urate was removed 
from the system, 2.7 µM urate hydroperoxide was formed and approximately 40% of 
GAPDH activity was lost. Hypoxanthine, lactoperoxidase and xanthine oxidase were 
essential for urate hydroperoxide formation. When they were removed from the system 
there was minimal loss of GAPDH activity. These controls provide strong evidence that 
the loss of GAPDH activity was due to urate hydroperoxide as opposed to superoxide, 
hydrogen peroxide or other products formed. 
 
4.3.3.2 Dose-Dependent Inactivation of GAPDH by Taurine Chloramine and 
Urate Hydroperoxide 
The purpose of this experiment was to determine the stoichiometry of GAPDH 
inactivation by taurine chloramine and urate hydroperoxide. GAPDH (1 µM) was 







Figure 24: Dose-dependent inactivation of GAPDH by taurine chloramine or urate hydroperoxide. 
Reduced GAPDH was incubated with for 10 min with varying concentrations of oxidant. The resulting 
activity of GAPDH was quantified by measuring the formation of NADH at 340 nm on a spectrophotometer. 
GAPDH activity was lost with increasing concentration of oxidant. The concentration of GAPDH was 
approximately 1 µM. This graph combines at least three experiments. 
 
Treatment of GAPDH with 10 µM taurine chloramine caused complete loss of 
activity (figure 24). The stoichiometry of inactivation for taurine chloramine to GAPDH 
was approximately 10:1. Urate hydroperoxide also showed dose-dependent inactivation 
of GAPDH. Approximately 5 µM urate hydroperoxide completely inactivated 1 µM 
GAPDH, hence the ratio of inactivation was approximately 5:1. The rate of inactivation 
was -18% activity per µM urate hydroperoxide. Urate hydroperoxide was a more 
successful inactivator of GAPDH than neutrophil derived oxidant taurine chloramine. 
  
4.3.4 Inactivation Kinetics for GAPDH  
I studied the kinetics of GAPDH inactivation by taurine chloramine and urate 
hydroperoxide to determine the reactivity of these oxidants. GAPDH was exposed to an 
oxidant in a discontinuous system and the resulting solution was immediately injected into 
the solution into assay cuvettes at different time points. Thus, the loss of GAPDH activity 
was measured with time. 



























Figure 25: Kinetics of GAPDH inactivation by oxidants. GAPDH was exposed to oxidants and the 
resulting activity was assayed at three time points. This method was repeated three times and the time points 
measured were staggered. Time = 0 was the GAPDH activity in catalase-treated phosphate buffer. A. Kinetics 
of GAPDH exposure to taurine chloramine. B. Kinetics of GAPDH inactivation by urate hydroperoxide. 
These graphs were representative of three experiments. 
 
Half of GAPDH activity was instantly lost upon exposure to taurine chloramine 
(figure 25 A). GAPDH activity continued to decline over the span of minutes. These results 
suggested GAPDH inactivation by taurine chloramine had two reactions: a fast and slow 
reaction. The fast reaction was not be characterised and represented the greater loss of 
GAPDH activity. The decline from 10 sec to 3 min represented a decline of approximately 
9% per min. The concentrations of GAPDH and taurine chloramine were approximately 1 
and 18 µM respectively. 
GAPDH exposure to urate hydroperoxide was met with a fast loss of GAPDH 
activity over 2 min (figure 25 B). The decline in activity was smooth, hence the cause of 
inactivation might be a one-step reaction. GAPDH activity declined at a rate of 
approximately 23% per min. For this experiment, a low concentration of urate 
hydroperoxide (approximately 3 µM) was used which only inactivated half of the enzyme. 
Inactivation of GAPDH with higher concentrations of urate hydroperoxide was too quick 
















































4.3.5 Reactivation of GAPDH with DTT 
This series of experiments explored whether inactivation of GAPDH by taurine 
chloramine or urate hydroperoxide was irreversible by reactivating the enzyme with DTT. I 
sought to confirm experiments by Peskin and Winterbourn (143) that taurine chloramine 
inactivation of GAPDH was reversible. GAPDH was exposed to taurine chloramine in a 
dose-dependent manner then samples were reduced with 2 mM DTT. 
 
Figure 26: Reactivation of GAPDH following inactivation with taurine chloramine. GAPDH was dose-
dependently exposed to taurine chloramine for 10 min. DTT (2 mM) was added to reactivate half of the 
samples and incubated for a further 30 min before measuring GAPDH activity. This graph combines at least 
three experiments. 
 
Figure 26 illustrates how GAPDH was reactivated following exposure to taurine 
chloramine. GAPDH treatment with taurine chloramine resulted in a dose-dependent loss 
of GAPDH activity as previously described (4.3.3.2). Reduction by DTT recovered at least 
80% of GAPDH activity regardless of taurine chloramine concentration. These results 
were similar to Peskin and Winterbourn (143) and confirms that taurine chloramine 
inactivation of GAPDH was reversible by reduction. Taurine chloramine likely inactivates 
GAPDH by forming disulfide bond with the essential thiol, and may pass through a 
sulfinic acid intermediate (143).  



























Figure 27: Reactivation of GAPDH following inactivation with urate hydroperoxide. GAPDH was dose-
dependently treated with urate hydroperoxide for 10 min. Half of the samples were reduced with 2 mM DTT 
and incubated the samples for a further 30 min before measuring GAPDH activity. This graph combines at 
least three experiments. 
 
Urate Hydroperoxide completely inactivated GAPDH, as shown in section 4.3.3.2. 
Reduction of the inactivated samples by DTT recovered approximately half of the activity 
lost (figure 27). This indicates GAPDH inactivation by urate hydroperoxide could be 
caused by reversible and irreversible modification. 
 
4.3.6 Depletion of Cysteine Residues on GAPDH by Oxidants 
This experiment served as a link between GAPDH inactivation and modification by 
oxidants. I wanted to determine whether cysteine residues on GAPDH were oxidized by 
taurine chloramine and urate hydroperoxide. The DTNB assay was performed on GAPDH 
discontinuously treated with oxidants in quartz cuvettes. Cysteine and GAPDH linearly 
absorbed light at 412 nm (Appendix 1, figure 42). The substances of the xanthine 
oxidase/lactoperoxidase system did not interfere with the assay (Appendix 1, figure 43). 
 
y = -18.192x + 100


























Figure 28: Dose-dependent depletion of cysteine residues on GAPDH by oxidants. A. Dose-Dependent 
depletion of GAPDH thiols by taurine chloramine. B. Dose-dependent depletion of cysteine residues on 
GAPDH by urate hydroperoxide. The final concentration of the GAPDH monomer was approximately 3 µM. 
These graphs combine three experiments which were normalised to a reduced thiol concentration of 36 µM.  
 
The DTNB assay of 3 µM GAPDH revealed 36 cysteine residues. Treatment of 
GAPDH with taurine chloramine oxidized 23 µM of the cysteine residues measured with 
DTNB (figure 28 A). The reduced thiol concentration plateaued at approximately 10 µM 
taurine chloramine. Similar results were seen for treatment of GAPDH with urate 
hydroperoxide (figure 28 B). Approximately 7 µM urate hydroperoxide was required to 
deplete 23 µM of cysteine residues on GAPDH. 
A GAPDH concentration of 3 µM should have produced 48 µM reduced thiols. 
However, as shown with the standard curve (Appendix 1, figure 42 B), one quarter of the 
cysteine residues on GAPDH were not measurable with DTNB. Thus, taurine chloramine 
and urate hydroperoxide depleted half of the cysteine residues on GAPDH. Previous 
studies determined that half of the cysteine residues on GAPDH were vulnerable to 
oxidants (27, 172). 
 
4.3.7 Polyacrylamide Gel Electrophoresis of GAPDH 
I performed SDS-PAGE on GAPDH samples treated with urate hydroperoxide to 


















































Figure 29: Non-reducing gel for the inactivation of GAPDH by urate hydroperoxide. GAPDH was 
exposed to urate hydroperoxide in a dose-dependent manner. The controls consisted of a protein marker, 
GAPDH and urate hydroperoxide. Lane 1: protein marker. Lane 2: 1.5 µM GAPDH. Lane 3: 10.5 µM urate 
hydroperoxide. Lane 4: 2.2 µM urate hydroperoxide + 1.5 µM GAPDH (approximately 3:2). Lane 5: 5.5 µM 
urate hydroperoxide + 1.5 µM GAPDH (7:2). Lane 6: 10.5 µM urate hydroperoxide + 1.5 µM GAPDH (7:1). 
 
Separation of samples under non-reducing conditions allowed visualisation of the 
quaternary structure of GAPDH (figure 29). The GAPDH control produced two major 
bands at approximately 36 and 37 kDa (lane 2). These species were likely the GAPDH 
monomers. The species formed above 75 kDa were impurity or other quaternary 
structures. The faint band at 150 kDa was likely the native homodimer of GAPDH (144 
kDa (173)). The xanthine oxidase/lactoperoxidase system (lane 3) produced bands at 16, 
60, 80 and 150 kDa. These bands represent superoxide dismutase monomer (16 kDa 
(174)), catalase monomer (57.5 kDa (175)), lactoperoxidase dimer (77.5 kDa (176)) and 
xanthine oxidase monomer (150 kDa (177)) respectively. Dose-dependent exposure of 
GAPDH to urate hydroperoxide (lanes 4 – 6) produced bands which were a combination 
of the two controls (lane 2 and 3). Thus there were no large molecular weight change for 





Figure 30: Reducing gel for the inactivation of GAPDH by urate hydroperoxide. GAPDH was exposed 
to urate hydroperoxide in a dose-dependent manner. The controls consisted of a protein marker, GAPDH and 
urate hydroperoxide. Lane 1: protein marker. Lane 2: 1.5 µM GAPDH. Lane 3: 10.5 µM urate 
hydroperoxide. Lane 4: 2.2 µM urate hydroperoxide + 1.5 µM GAPDH (approximately 3:2), Lane 5: 5.5 µM 
urate hydroperoxide + 1.5 µM GAPDH (7:2). Lane 6: 10.5 µM urate hydroperoxide + 1.5 µM GAPDH (7:1). 
 
Separation of samples under reducing conditions allowed visualisation of the 
tetrameric structure of GAPDH (figure 30). GAPDH ran as a single band at 
approximately 36 kDa in reducing conditions (lane 2). This band represented the 
GAPDH monomer. The major bands for the xanthine oxidase/lactoperoxidase system 
were the same as non-reducing conditions (figure 29) (lane 3). Dose-dependent 
exposure of GAPDH to urate hydroperoxide produced a combination of bands seen in 
the controls (lane 4 – 6). A faint band formed at approximately 70 kDa which was not 
present in the GAPDH or urate hydroperoxide samples. However, it was too faint to be 
a significant modification. The results for reducing and non-reducing conditions were 
consistent. There was no major change in GAPDH’s molecular weight following 





4.3.8 Mass Spectrometry of GAPDH 
Using mass spectrometry, I hoped to identity modifications to residues to explain the 
loss of GAPDH activity following exposure to urate hydroperoxide. All work with the 
mass spectrometer and analysis was carried out by Dr. Louise Paton. I prepared the 
samples for mass spectrometry and performed the tryptic digest. GAPDH was treated with 
urate hydroperoxide and/or DTT. The samples ran through the mass spectrometer as 
complete proteins. 
 
Table 5: Species found during whole protein mass spectrometry of GAPDH treated with a low 
concentration of urate hydroperoxide. For this experiment a ratio of 1:1 GAPDH to urate hydroperoxide 
was used. Only species that represented > 5% of the total were listed. The GAPDH monomer and the species 
that may have an adduct were highlighted yellow.  






























35,734 0 28.1 35,732 0.0 48 35,732 0 38 35,734 0 41.2 
35,691 -43 26.1 35,807 75 32 35,805 72 34 35,810 77.4 27.7 
35,775 41 24.2 35,877 145 7 35,865 132 13 35,865 132 10.7 
35,846 112 11.4          
 
The mass spectrums had a small population of species at 36 kDa, indicating HPLC 
successfully separated GAPDH (Appendix 1, figure 44). The species found per sample and 
delta masses were presented in table 5. The m/z values for the GAPDH monomer was seen 
in sample A. The species found were approximately 36 kDa and differed by 155 Da. When 
DTT was added (sample B) the 35,732 Da species became distinct and likely represented 
the reduced GAPDH monomer. GAPDH was treated with urate hydroperoxide (sample C) 
and three major species were found. The main species represented the reduced GAPDH 
monomer (35,732 Da). The 35,805 Da species had a similar molecular weight and percent 
to a species formed when GAPDH was reduced with DTT (35,807 Da) (samples B). Thus, 
this species was not unique to urate hydroperoxide treatment. Of interest was the species 
with a molecular weight of 35,865 Da (sample C). This species was formed during urate 
hydroperoxide treatment and remained after DTT reduction (sample D).  A delta mass of 




The 35,865 Da species of sample C may have been the cause of irreversible 
inactivation of GAPDH following treatment with urate hydroperoxide. A delta mass of 132 
indicated the formation of a urate adduct. However, the molecular weight of urate was 168. 
The purine ring of urate may have degraded during mass spectrometry to lose atoms. A 
tryptic digest of GAPDH with trypsin was performed and the resulting peptides were 
measured with tandem mass spectrometry. The sequence coverage of GAPDH by the 
peptides was too low to determine the oxidative modification to GAPDH. 
 
4.4 Discussion 
Urate hydroperoxide is a powerful oxidant of thiol-dependant GAPDH. When I 
exposed GAPDH to urate hydroperoxide the activity was lost in a dose-dependent manner. 
The inactivation ratio for urate hydroperoxide to GAPDH was 5:1. In comparison, taurine 
chloramine required twice the concentration to inactivate the same concentration of 
GAPDH. Urate hydroperoxide was therefore a stronger oxidant of GAPDH than taurine 
chloramine and hydrogen peroxide (143). DTT only recovered half of GAPDH activity 
following inactivation by urate hydroperoxide. The same concentration of DTT completely 
removed the effects of taurine chloramine on GAPDH. These results indicate urate 
hydroperoxide partially permanently inactivates GAPDH. Permanent inactivation of 
enzymes affect a cell’s ability to survive and proliferate since the enzyme would have to be 
broken down and replaced (24).  
Neither taurine chloramine nor urate hydroperoxide completely oxidized the cysteine 
residues on GAPDH during the DTNB assay. This finding was consistent with previous 
work by Ishii et al. (27). Of the four cysteine residues on the GAPDH monomer, Cys149 
and Cys153 quickly cleave DTNB, whereas Cys244 and Cys281 reacts slowly with DTNB. 
Oxidants only deplete Cys149 and Cys153, hence the DTNB assay measures 
approximately half the reduced thiols following oxidant treatment (27). Urate 
hydroperoxide depletion of cysteine residues on GAPDH was too variable to determine the 
stoichiometry of depletion. This may become apparent with repeat experiments. Future 
experiments could include measurement of the kinetics of oxidation of cysteine residue on 
GAPDH with the DTNB assay. 
Urate hydroperoxide increased the mass of the GAPDH monomer by 132 Da during 




the molecular weight of urate is 168 Da and it is difficult to speculate what loss of mass 
allows an addition of 132 Da. The purine ring may have collapsed resulting in the loss of 
some atoms. Urate adducts of 140 and 166 Da have been seen in our lab (Rufus Turner, 
unpublished data).  A tryptic digest was performed on GAPDH treated with urate 
hydroperoxide however the sequence coverage for the resulting peptides was only 35%. 
This coverage was too poor to determine which residue the urate formed on. The tryptic 
digest must be optimised to deliver more GAPDH peptides. This could be achieved by 
performing a double protease digest with trypsin and chymotrypsin to maximise the 
number of cleavage sites. I plan to perform a trypsin/chymotrypsin digest, followed by 
























Chapter 5. Conclusions 
5.1 Summary of Findings 
My research describes a new mechanism for urate acting as pro-oxidant through 
formation of the novel oxidant urate hydroperoxide. I studied the formation and reactivity 
of urate hydroperoxide with thiols. An enzyme system with xanthine oxidase and 
lactoperoxidase was used to form urate hydroperoxide. The concentration of this oxidant 
was measured with the FOX assay. Urate hydroperoxide formation was optimised using a 
maximum concentration of hypoxanthine, urate and xanthine oxidase. The optimised 
system formed approximately 15 µM urate hydroperoxide in 20 min at initial rate 3.2 
µMmin-1. This was a useful concentration for future experiments. Urate hydroperoxide 
depleted cysteine and glutathione. The depletion of glutathione by urate hydroperoxide was 
at a 2:1 ratio, which implies glutathione was oxidised to glutathione disulfide and did not 
form an adduct. 
Urate hydroperoxide caused a dose-dependent loss of activity in thiol-dependent 
enzyme GAPDH. The ratio of inactivation was approximately 5:1. The inactivated enzyme 
was reduced with DTT and half of the activity was recovered. Hence, urate hydroperoxide 
partially, permanently inactivates GAPDH. Using mass spectrometry I identified a 132 Da 
increase in mass of GAPDH after treatment with urate hydroperoxide. This modification 
could be a urate adduct, however I could not confirm this theory with a tryptic digest 
followed by tandem mass spectrometry. Urate hydroperoxide oxidised half of the cysteine 
residues on GAPDH and may have formed the urate adduct to the catalytic cysteine. 
However, I could not confirm oxidation of cysteine was responsible for permanent loss of 
activity. Overall, these results suggest that urate hydroperoxide could be a strong oxidant 
of thiol-dependent enzymes. The mechanism of inactivation requires more work to 
elucidate. 
Urate hydroperoxide may be produced by neutrophil oxidative bursts during 
hyperuricemia (figure 31). Thus, this research links hyperuricemia and tissue damage 
leading to inflammatory disease. Urate hydroperoxide could deplete cysteine and 
glutathione, hence starving the cell of essential biomolecules and aggravating oxidative 
stress. Thiol-dependent enzymes; such as glycolytic enzymes, protein tyrosine phosphatase 
and cysteine protease; could be irreversible inactivated by urate hydroperoxide. Since 




lead to loss of cell function and death. Factors secreted during apoptosis or necrosis 
recruits inflammatory cells. This is positive feedback for inflammation, oxidative stress 
and urate hydroperoxide formation. 
 
 
Figure 31: Neutrophil activity at inflammatory sites, during hyperuricemia, could produce urate 
hydroperoxide. Membrane-bound NADPH oxidase generates superoxide using NADPH as a cofactor. 
Superoxide can dismutate to hydrogen peroxide, which is a substrate for neutrophil myeloperoxidase. 
Myeloperoxidase produces hypochlorous acid from chloride and hydrogen peroxide. It also converts urate to 
a radical. Superoxide and the urate radical are in proximity to combine and form urate hydroperoxide. Figure 
adapted from (108). 
 
Urate hydroperoxide formation explains the pro-oxidant effects of urate during 
hyperuricemia. Previous studies found that urate promoted lipid peroxidation and enzyme 
inactivation. Urate hydroperoxide may have formed during these experiments and led to 
the oxidation of the biomolecules studied. For example, urate hydroperoxide may have 
formed during Aruoma and Halliwell’s (91) radiolysis of A1AT. A1AT relies on a cysteine 
residue for activity, thus urate hydroperoxide may have formed an adduct to this enzyme 
analogous to my findings with GAPDH (178). In support of this, the authors proposed a 
urate peroxyl radical inactivated the enzyme. Peroxyl radicals degrade to hydroperoxides, 





5.2 Strengths and Limitations 
To the best of my knowledge, no other study has measured urate hydroperoxide’s 
effect on enzymes. I presented strong in vitro evidence that urate hydroperoxide inactivates 
GAPDH. Urate hydroperoxide inactivation of thiol-dependent enzyme GAPDH is new and 
important for understanding the pro-oxidant effects of urate during hyperuricemia. My 
research provides a new mechanism for the numerous pro-oxidant effects of urate, which 
were previously unexplained. This research paves the way for in-depth research on urate 
hydroperoxide.  
A major limitation of this study is that there is no evidence urate hydroperoxide is 
formed in vivo. However, neutrophils, which are abundant at inflammatory sites, have all 
the machinery to produce this oxidant. Measuring urate hydroperoxide’s presence in vivo is 
difficult due to its reactive and transient nature. The formation of a urate adduct to thiol-
dependent enzymes could be used as a biomarker for urate hydroperoxide’s formation in 
vivo. I cannot discern urate hydroperoxide’s effect on all thiol-dependent enzymes based on 
its inactivation of GAPDH. A diverse pool of thiol-dependent enzymes should be studied to 
conclude that urate hydroperoxide inactivates thiol-dependent enzymes in general. 
In this thesis I postulated that urate hydroperoxide could be formed at an 
inflammatory site extracellularly. However for urate to have a significant effect on thiols it 
must be uptaken into cells through a urate transporter. Urate is uptaken into vascular 
smooth muscle cells though anion transporter URAT1 (179), urate hydroperoxide could 
also be uptaken through this transporter. However, whether urate transporters allow uptake 
of oxidised urate has not been explored.  
My work was completely in vitro and therefore has limited applicability to in vivo. In 
vitro experiments place the substrates in a proximity that might not be achieved in vivo. 
For example, urate hydroperoxide formation at an endothelium inflammatory site might be 
hindered by blood flow washing away the proteins. Also, neutrophils may only form urate 
hydroperoxide when the inflammatory site is overwhelmed by oxidative stress because 
antioxidants like ascorbate and glutathione reduce oxidants. During oxidative stress there 
would be a multitude of other oxidants which could be as powerful as urate hydroperoxide. 
At best, I argue that urate hydroperoxide could contribute to tissue damage by oxidative 





5.3 Recommendation for Future Work 
There is strong evidence that urate hydroperoxide inactivates GAPDH but I could not 
identify the modification. GAPDH treated with urate hydroperoxide may form an adduct, 
however the results from the tryptic digest were too poor to support this. I hope to optimise 
the tryptic digest and characterise the oxidative modification to GAPDH in the future. 
This thesis described urate hydroperoxide’s inactivation of one thiol-dependent 
enzyme. My work must be extended to other thiol-dependent enzymes such as protein 
tyrosine phosphatase, protein tyrosine kinase and other glycolytic enzymes. Urate 
hydroperoxide inactivation of these enzymes will build a picture of this oxidant’s reactivity 
with thiol-dependent enzymes. Also, urate hydroperoxide could oxidise other biomolecules. 
In particular, urate hydroperoxide’s depletion of ascorbate should be characterised. Urate 
hydroperoxide’s ability to oxidise past the lipid-water barrier could also be characterised 
by measuring the oxidation of lipids and lipid-soluble antioxidants such as coenzyme, α-
tocopherol and carotenes. 
To give this research cellular context I suggest exposing cells and bacteria to urate 
hydroperoxide and measuring the change of cell viability. However, this requires urate 
hydroperoxide uptaken into cells and use of an appropriate cell model. Since the 
pathological context of this research is hyperuricemia I suggest cells to model the human 
endothelium. Cells could be exposed to hyperuricemia and the xanthine 
oxidase/lactoperoxidase system to make urate hydroperoxide in situ. Whether urate 
hydroperoxide could be uptaken by urate transporters should be explored. Additionally, we 
could determine the viability of urate hydroperoxide formation in vivo by exposing 
neutrophils to hyperuricemic conditions during their oxidative bursts and measuring 
hydroperoxide formation. There is also the possibility of creating antibodies for the urate 
adduct to GAPDH. This would allow detection of urate hydroperoxide’s oxidation of 
GAPDH in cells. 
The formation of urate adducts to enzymes has potential as a biomarker of urate 
hydroperoxide formation in vivo. Future experiments could include spiking clinical plasma 
samples with urate hydroperoxide and performing mass spectrometry to detect the 
formation of adducts on isolated thiol-dependent enzymes, depletion of antioxidants and 
other oxidized species. Also, urate adducts could be developed as a biomarker for 




clinical samples from patients suffering hyperuricemia and a control population and 
correlating to risk of heart disease.  
I will be continuing this project as summer studentship wherein I will study urate 
hydroperoxide inactivation of protein tyrosine phosphatase and the protective effects of 
ascorbate. I will optimise the riboflavin photooxidation system for urate hydroperoxide 
formation. The possibilities for future work with urate hydroperoxide are numerous and 
exciting. Research into this novel oxidant could provide a mechanism for hyperuricemia’s 
pro-oxidant effects, therefore advancing our understanding of its association with 
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Appendix 1: Supplementary Figures 
 
Figure 32: Standard curve for the FOX assay based on H2O2 absorbance at 560 nm. The absorbance of 
hydrogen peroxide was linear at 560 nm. This standard curve was used to determine the concentration of 
urate hydroperoxide with the FOX assay. The assumption must be made that urate hydroperoxide oxidized 
Fe2+ at the same stoichiometry as hydrogen peroxide. This graph was the mean of three experiments. The 
error bars represented the standard deviation of three experiments. 
 
 
Figure 33: FOX assay of each substance required to form urate hydroperoxide. The final concentration 
of substances were: 100 µM hypoxanthine, 100 µM urate, 200 nM lactoperoxidase 0.9 µM xanthine oxidase, 
100 µg/mL catalase and 10 µg/mL superoxide dismutase. None of the substances produced a significant 
concentration of hydroperoxide compared to the phosphate buffer control. This graph was the mean of two 
experiments. The error bars represented the standard deviation for the two experiments. One-way ANOVA 
followed by Holm-Sidak multiple comparison was performed on the mean of two experiments to identify 















































Figure 34: Thiol standard curve and xanthine oxidase/lactoperoxidase system controls with the DTNB 
assay. A. Standard curve for DTNB absorbance at 412 nm vs. concentration of cysteine, glutathione, cystine 
and glutathione disulfide. Cysteine and glutathione produce linear absorbance at 415 nm. The absorbance for 
cystine and glutathione was negligible. B. DTNB assay of all substances of the xanthine 
oxidase/lactoperoxidase system: 50 mM phosphate buffer, 78 µM hypoxanthine, 195 µM urate, 156 nM 
lactoperoxidase, 1.4 µM xanthine oxidase, 78 µg/mL catalase and 7.8 µg/mL superoxide dismutase. The 
absorbance of hypoxanthine, xanthine oxidase and superoxide were negligible. The absorbance for urate, 
lactoperoxidase and catalase were small but significant. These graphs represented one experiment. The error 
bars represented the standard deviation for triplicate readings. One-way ANOVA followed by Holm-Sidak 
multiple comparison on triplicate readings was used to identify samples that were significantly different from 































































Figure 35: Depletion of free thiols by urate hydroperoxide controls. A. DTNB assay of depletion of 
cysteine by the substances of the xanthine oxidase/lactoperoxidase system. Hypoxanthine, xanthine oxidase 
and superoxide dismutase did not significantly affect the cysteine concentration. However, lactoperoxidase 
depleted three quarters of cysteine. Catalase caused a 1 µM increase in reduced thiol concentration due to its 
interaction with DTNB. B. DTNB assay of depletion of glutathione by the substances used of the xanthine 
oxidase/lactoperoxidase system. Catalase caused a 1 µM increase in reduced thiol concentration, whereas all 
other substances caused a 1 µM loss. These graphs were representative of two experiments. Error bars were 
based standard deviation for triplicate readings. One-way ANOVA followed by Holm-Sidak multiple 
comparison on triplicate readings was used to identify samples that were significantly different from thiols in 
phosphate buffer (* p <0.05). 
 
 
Figure 36: Standard curve for GAPDH concentration vs. initial activity. The assay cuvette contained 2 
mM DTT. Initial GAPDH activity increased linearly with enzyme concentration. The concentration of 
GAPDH used for proceeding assays were > 60 nM. This graph represented one experiment. The error bars 
















































































Figure 37: GAPDH concentration and activity during spin column preparation. A. GAPDH 
concentration during spin column preparation. A small dilution was seen with DTT treatment. Two thirds of 
GAPDH was lost when the protein was isolated with spin columns. B. GAPDH activity during spin column 
preparation. GAPDH activity increased significantly when the enzyme was treated with DTT. Following 
isolation with spin columns, the GAPDH activity dropped due to the loss of protein. Reduction of GAPDH 
with DTT was necessary to achieve a measurable activity, even though a significant amount of protein was 
lost. These graphs represented one experiment. The error bars represented the standard deviation for triplicate 
readings. 
 
Figure 38: NAD standard curves for absorbance at 260 and 340 nm. A. NAD+ standard curve at 260 nm. 
NAD+ absorbance was linear with extinction coefficient 50,800 M-1 cm-1, absorbance at 340 nm was 
negligible. B. NADH standard curve at 340 nm. NADH absorbance was linear with the extinction coefficient 
4,100 M-1 cm-1. Absorbance at 340 nm was exclusive to NADH, hence it can be used to show the loss or 
formation of this oxidation state. These graphs represented one experiment and error bars represented 









































































































Figure 39: Dose-dependent exposure of NAD to taurine chloramine. A. Treatment of NAD+ to taurine 
chloramine at 260 nm. Taurine chloramine did not significantly change the absorbance at 260 or 340 nm, 
hence taurine chloramine does not reduce this cofactor. B. Treatment of NADH to taurine chloramine at 340 
nm. Taurine chloramine caused a loss of absorbance for NADH which plateaued at half of the initial 
absorbance. The initial ratio of depletion for NADH to taurine chloramine was 1:2. High concentrations (> 80 
µM) were required to deplete half of NADH. The interaction of taurine chloramine with NAD would not 
significantly affect the GAPDH assay since the concentrations of these substances were low. These graphs 
represented one experiment and the error bars are standard deviation for triplicate readings. 
 
 
Figure 40: Dose-dependent exposure of NAD to urate hydroperoxide. A. Dose-dependent treatment of 
NAD+ with urate hydroperoxide and measurement of absorbance at 260 nm. B.: Dose-dependent treatment of 
NADH with urate hydroperoxide and measurement of absorbance at 340 nm. Urate hydroperoxide did not 
significantly change the absorbance at 260 or 340 nm for either oxidative states. Urate hydroperoxide does 
not seem to oxidatively interact with either of these molecules at concentrations that could be formed during 
exposure of GAPDH to urate hydroperoxide. These graphs represented one experiment. The error bars 
represented the standard deviation for triplicate readings. 












































































Figure 41: GAPDH activity following exposure to the substances of the xanthine 
oxidase/lactoperoxidase system. GAPDH in phosphate buffer represented 100% activity. The concentration 
of substances was the same as later experiments where GAPDH was treated with urate hydroperoxide: 90 
µM hypoxanthine, 360 µM urate, 190 nM lactoperoxidase, 1.6 µM xanthine oxidase. All substances had > 80% 
activity compared with the phosphate buffer control. This graphs represented one experiment. The error bars 
represented the standard deviation for triplicate readings. One-way ANOVA followed by Holm-Sidak 
multiple comparison on triplicate readings was used to identify samples that were significantly different from 
the phosphate buffer control (* p <0.05). 
 
 
Figure 42: Standard curve of GAPDH concentration vs. reduced thiol concentration during the DTNB 
assay in a quartz cuvette. Approximately 12 thiols per micromolar GAPDH were measured. This equated to 
12 cysteine residues per GAPDH tetramer. GAPDH has four cysteine residues per subunit, hence four thiols 
per GAPDH tetramer did not react with DTNB under these conditions. These graphs represented one 













































Figure 43: Depletion of cysteine residues on GAPDH by the xanthine oxidase/lactoperoxidase system. 
GAPDH (3 µM) was incubated with 50 mM phosphate buffer, 90 µM hypoxanthine, 360 µM urate, 190 nM 
lactoperoxidase, 1.7 µM xanthine oxidase, 95 µg/mL catalase and 9.5 µg/mL superoxide dismutase. The 
DTNB assay was performed in quartz cuvettes. Compared with phosphate buffer, hypoxanthine and 
lactoperoxidase had no effect on the reduced thiol concentration. Urate, xanthine oxidase, catalase and 
superoxide dismutase increased the reduced thiol concentration. One-way ANOVA followed by Holm-Sidak 
multiple comparison on triplicate readings was used to identify samples that were significantly different from 


































Figure 44: Mass Spectrum for the GAPDH and urate hydroperoxide experiment treated with urate 
hydroperoxide (1:1 ratio). A: GAPDH isolated with spin columns. B: GAPDH reduced DTT. C: GAPDH 
exposed to urate hydroperoxide. D: GAPDH exposed to urate hydroperoxide and reduced with DTT. These 

















Appendix 2: Supplementary Methods and Materials 
5.1 Chapter 2 
Table 6: Volumes of substances used for the FOX assay of urate hydroperoxide formation. Each sample 
represented the full system, removal of a substance or addition of superoxide dismutase. When urate 






























- 3 3 3 3 3 
1 mM 
Urate 
30 - 30 30 30 30 
5.7 µM 
LPO 
17 17 - 17 17 17 
90 µM 
XO 
3 3 3 - 3 3 







































5.2 Chapter 3 
Table 7: Samples made for the xanthine oxidase/lactoperoxidase system which was subsequently used 
to treat 70 µM cysteine or 30 µM glutathione. Samples A-G represented the full system or controls where 
each substance was removed or quencher added. After 10 min incubation the reaction was stopped with 
catalase and superoxide dismutase. Samples (780 µL) were transferred into plastic cuvettes with cysteine or 
glutathione. 
































- 33 33 33 33 33 33 
1 mM 
Urate 
825 - 825 825 825 825 825 
5.7 µM 
LPO 
115.8 115.8 - 115.8 115.8 115.8 115.8 
90 µM 
XO 
66 66 66 - 66 66 66 




- - - - - 165 - 
2 mg/mL 
Cata 

































Table 8: Samples made for dose-dependent treatment of cysteine and glutathione with taurine 
chloramine. Taurine chloramine (20 µM) was mixed at an increasing volume to 25 µM cysteine or 15 µM 
glutathione. The volume of each sample was equalled with phosphate buffer. After10 min the DTNB assay 
was performed. 













Blank 0 0 0 0 980 20 
PB 
Control 
0 25 200 0 780 20 
Tau-Cl 
Control 
15.6 0 0 780 0 20 
1 2 25 200 100 680 20 
2 4 25 200 200 580 20 
3 6 25 200 300 480 20 
4 8 25 200 400 380 20 
5 10 25 200 500 280 20 
6 12 25 200 600 180 20 















0 15 200 0 780 20 
8 2 15 200 100 680 20 
9 4 15 200 200 580 20 
10 6 15 200 300 480 20 
11 8 15 200 400 380 20 
12 10 15 200 500 280 20 
13 12 15 200 600 180 20 






















Table 9: Samples made for dose-dependent exposure of glutathione to urate hydroperoxide. An 
increasing volume of urate hydroperoxide was added to 30 µM glutathione. The volume was equalled with 
phosphate buffer. Control samples, with the xanthine oxidase/lactoperoxidase system without hypoxanthine, 




Volumes in Plastic Cuvettes (µL) 













Blank 0 0 0 0 - 980 20 
PB 
Control 
0 30 200 0 - 780 20 
1 0 30 200 - 100 680 20 
2 0 30 200 - 200 580 20 
3 0 30 200 - 300 480 20 
4 0 30 200 - 400 380 20 
5 0 30 200 - 500 280 20 
6 0 30 200 - 600 180 20 







0 200 780 - 0 20 
8 1.2 30 200 100 - 680 20 
9 2.3 30 200 200 - 580 20 
10 3.5 30 200 300 - 480 20 
11 4.7 30 200 400 - 380 20 
12 5.9 30 200 500 - 280 20 
13 7 30 200 600 - 180 20 
14 9.1 30 200 780 - 0 20 
 
5.3 Chapter 4 
Table 10: Xanthine oxidase/lactoperoxidase system in the quartz cuvette during continuous 
inactivation of GAPDH. These substances were accompanied by the substances for the GAPDH assay. The 
two initiators, xanthine oxidase and GAPDH, were added last to start both systems. 






























830 525 765 550 353 515 465 465 
10 mM 
HX 
- - 10 10 10 10 10 10 
1 mM 
Urate 
- 250 - 250 250 250 250 250 
5.7 µM 
LPO 
- 35 35 - 35 35 35 35 
90 µM XO - 20 20 20 - 20 20 20 
0.2 mg/mL 
SOD 
- - - - - - 50 - 
2 mg/mL 
Cata 





Table 11: Xanthine oxidase/lactoperoxidase system samples used to treat GAPDH. Samples A-G 
represented the xanthine oxidase/lactoperoxidase system with controls where each substance removed or 
quenchers were added. After 20 min incubation the formation of urate hydroperoxide was stopped with 
catalase and superoxide dismutase. 
























final vol.  
300µL 
10 mM HX - 3 3 3 3 3 3 
1 mM Urate 120 - 120 120 120 120 120 
5 µM LPO 12 12 - 12 12 12 12 
90 µM XO 6 6 6 - 6 6 6 
50 mM PB 279 159 171 165 159 144 144 
0.2 mg/mL 
SOD 
- - - - - 15 - 
2 mg/mL 
Cata 








14 14 14 14 14 14 14 
0.2 mg/mL 
SOD 
14 14 14 14 14 14 14 
 
Table 12: Sample composition for GAPDH reactivation experiment following inactivation by taurine 
chloramine. This experiment involved two sets of samples to represent before and after DTT treatment. The 
concentration of taurine chloramine was varied by adding different volumes of a 20 µM solution and 
equalling the volume with catalase-treated phosphate buffer. 
` Samples Final Concentration of 
Substances (µM) 
Volume of Substances used (µL) 















18 0 0 0 180 4 0 
1 3 1 0 20 30 154 0 
2 6 1 0 20 60 124 0 
3 9 1 0 20 90 94 0 
4 12 1 0 20 120 64 0 
5 15 1 0 20 150 34 0 





18 0 0 0 180 0 4 
PB 
Control 
0 1 200 20 0 180 4 
7 3 1 200 20 30 150 4 
8 6 1 200 20 60 120 4 
9 9 1 200 20 90 90 4 
10 12 1 200 20 120 60 4 
11 15 1 200 20 150 30 4 







Table 13: Sample composition for the GAPDH reactivation experiment following inactivation by urate 
hydroperoxide. This experiment involved two sets of samples to represent before and after DTT treatment. 
The concentration of urate hydroperoxide was varied by adding different volumes of a 7 µM solution and 
equalling the volume with catalase-treated phosphate buffer. 
` Samples Final Concentration of 
Substances (µM) 
Volume of Substances used (µL) 















5.7 0 0 0 180 4 0 
1 0.9 1 0 20 30 154 0 
2 1.9 1 0 20 60 124 0 
3 2.8 1 0 20 90 94 0 
4 3.8 1 0 20 120 64 0 
5 4.7 1 0 20 150 34 0 





5.7 0 0 0 180 0 4 
PB 
Control 
0 1 200 20 0 180 4 
7 0.9 1 200 20 30 150 4 
8 1.9 1 200 20 60 120 4 
9 2.8 1 200 20 90 90 4 
10 3.8 1 200 20 120 60 4 
11 4.7 1 200 20 150 30 4 
12 5.7 1 200 20 180 0 4 
 
5.3.1 Mass Spectrometry 
GAPDH samples (0.5 μg) were injected onto an Accucore-150-C4 (50 x 2.1 mm, 2.6 
µM, Thermo Scientific) column using a Dionex Ultimate 3000 HPLC system (Thermo 
Scientific). Proteins were eluted from the column (60˚C) with an acetonitrile gradient from 
9:1 of solvent A:B (table 4) to 2:8 over 4.6 mins. The flow rate of the mobile phase was 
400 µL/min. The eluted protein was passed to a Velos Pro mass spectrometer. Mass 
spectral data was taken between m/z 400 and 2000 on positive ion mode. Proteins peaks 
were averaged and deconvoluted using ProMass for Xcalibur (version 2.8). The tune file 
was set to capillary temperature of 275°C and spray voltage of 4 kV. Three microscans 
were averaged, the maximum inject time was 10 ms and automatic gain control target 
settings were 3 × 104 in full mass spectrometry and 1 × 104 in multi-stage mass 
spectrometry. 
